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CHAPTER 1: INTRODUCTION
Background and Clinical Significance
Kidney Structure
Each kidney, about the size of a fist and located on either side of the spine, is made up of
approximately one million functioning units called nephrons. Each nephron includes a glomerulus,
surrounded by a single layer of epithelium called the Bowman's capsule, and a long tubule which
consists of a proximal portion and a distal portion connected by a loop of Henle. The tubule joins
a collecting duct which joins larger ducts, eventually draining into the renal pelvis (Figure 1).
Blood enters the glomerulus via the afferent arteriole, and filtered blood (ultrafiltrate) is
carried away from the glomerulus via the efferent arteriole. Both the afferent and efferent arterioles
have a muscular layer which allows them to dilate or constrict (Figure 1) [1-3].
Kidney Function
The kidneys are best known for their role in excreting metabolic waste products through
urine production; however, these organs are responsible for other essential tasks, such as regulating
blood volume, maintaining acid-base balance, and assuring bone integrity and blood pressure
control. The nephrons of the kidney regulate blood composition within a narrow physiologic range
via three main processes: filtration, reabsorption, and secretion.
Glomeruli in the nephrons are responsible for generating ultrafiltrate of the plasma.
Filtration is based on size and charge, where small solutes (e.g., glucose, urea, insulin, and ions –
sodium, potassium, bicarbonate, and chloride) are able to readily cross the filtration barrier, larger
substances (e.g., cells and immunoglobulins) are generally excluded, and negatively charged
molecules such as large plasma proteins (e.g., albumin) are restricted.
As the ultrafiltrate flows from the Bowman’s capsule of the glomerulus through the
tubules, its composition changes as solutes and water are reabsorbed out of the ultrafiltrate (tubular
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reabsorption) and substances such as hydrogen ions, creatinine, and xenobiotics are removed from
the blood through the peritubular capillary network into the collecting duct (tubular secretion) [1,
4].
Any substance that has not been reabsorbed during glomerular filtration or tubular
reabsorption is excreted in the urine, which is composed of 95% water and 5% various solutes, of
which 60% is nitrogenous waste (urea, uric acid, creatinine, and ammonia) and 40% is inorganic
salts (sodium chloride, calcium phosphate, calcium sulfate, sodium, potassium, and magnesium).
The kidneys are also responsible for producing and releasing three important hormones:
erythropoietin, calcitriol (1,25-dihydroxycholecalciferol or 1,25(OH)2 D), and renin.
Erythropoietin is a peptide hormone which stimulates red blood cell production in the bone
marrow. Calcitriol is the biologically active form of vitamin D; the proximal tubule of the kidney
provides the enzyme, 1-alpha hydroxylase, responsible for the final hydroxylation reaction in
converting calcifediol to calcitriol. Renin helps regulate blood pressure and fluid balance; this
enzyme is released by the granular cells in the juxtaglomerular apparatus of the kidneys in response
to a fall in arterial blood pressure or sodium levels. Additionally, the kidneys have metabolic roles,
such as metabolizing certain drugs and endogenous substances such as insulin, as well as some
capacity to conduct gluconeogenesis [5-7].
Epidemiology of Chronic Kidney Disease (CKD)
CKD cause can be classified by the presence of underlying systemic disease, such as
diabetes mellitus (DM), autoimmune disorders, and genetic disorders, or by diagnosis of an
anatomic abnormality of the kidney (i.e., glomerular, tubulointerstitial, vascular, or congenital).
Clinical, sociodemographic, genetic, and epigenetic risk factors may contribute to CKD
risk. The two primary clinical risk factors for kidney damage in the United States (U.S.) are DM
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and hypertension (HTN). Other clinical risk factors include nephrotoxic medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), obesity, kidney stones, and smoking. Since many
patients fail to receive nephrology care prior to diagnosis, the actual cause of their CKD may be
attributed erroneously to DM or HTN, leading to over reporting of these two conditions [8].
Among the sociodemographic factors that contribute to increased CKD risk are nonwhite
race, progressive age > 60, low education, and low income.
Genetic risk factors include apolipoprotein L1 (APOL1) risk alleles, polycystic kidney
disease, sickle cell trait and disease, and congenital anomalies such as glomerulocystic kidney
disease (GCKD). Several single gene disorders, such as GCKD, are known as “monogenic
diseases” or mutations of a single gene and are fully penetrant and thus evident from birth or early
childhood. Genetic disorders which affect multiple genes are polygenic, such as autosomal
dominant polycystic kidney disease, and typically present later in life [9, 10].
Epigenetics may also play a role in CKD development and explain susceptibility to
comorbidities such as obesity or DM. Environmental and lifestyle factors, such as diet, nutrition,
behavior, stress, and physical activity, can result in inflammation, oxidative stress, and uremia,
which induce epigenetic changes leading to renal fibrosis and CKD development [11, 12].
Pathophysiology and Risk Factors for CKD
CKD is a condition generally characterized by a slow and progressive loss of kidney
function over time as a result of several heterogeneous disease pathways that irreversibly alter the
function and structure of the kidney. Renal fibrosis, which is the unsuccessful wound healing of
kidney tissue after chronic, sustained injury, is the final common pathological manifestation
resulting from a variety chronic kidney diseases. This fibrotic tissue in the kidneys is a buildup of
scar within the parenchyma and is characterized by glomerulosclerosis, tubular atrophy, and
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interstitial fibrosis. Risk factors for progressive glomerulosclerosis, or scarring or hardening of the
glomeruli, include hyperglycemia, HTN, dyslipidemia, and smoking [13, 14].
Clinical Presentation of CKD
The kidney possesses a huge physiologic reserve which can explain why most CKD
patients are asymptomatic until more than 75% of kidney function is lost. As CKD progresses,
kidney function becomes less effective, leading to the accumulation of uremic retention solutes
and uremic toxins that can exert adverse biological effects in the body. These toxins are believed
to contribute to inflammation, immune dysfunction, cardiovascular disease (CVD), gut dysbiosis,
and further CKD progression. Uremic retention solutes can be subdivided into three groups based
on their solubility, binding capacity, and molecular size: (1) small water soluble compounds (i.e.,
urea, polyamines, and oxalates), (2) small protein-bound or lipid soluble compounds
(homocysteine and indoles), and (3) larger (over 500 Da) middle-molecules (β2 microglobulin,
parathyroid hormone, and advanced glycosylation end [AGE] products).
Diagnosis of CKD
Estimated glomerular filtration rate (GFR), a measure of kidney function, and albuminuria,
a marker of kidney damage, are the two main tests used to detect and stage chronic kidney disease.
GFR, which equals the total amount of fluid filtered through all of the functioning nephrons per
unit of time, is calculated from serum creatinine or cystatin C levels using an estimating equation
(e.g., the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] [15] and Modification
of Diet in Renal Disease Study [MDRD] [16] equations) in combination with age, race, and gender,
whereas albuminuria is directly measured from urine as albumin to creatinine ratio. Current
Kidney Disease Improving Global Outcomes (KDIGO) guidelines define CKD, regardless of
underlying cause, as decreased kidney function evidenced by GFR of < 60 mL/min per 1.73 m²,
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or albumin to creatinine ratio > 30 mg/g, or both, for at least 3 months (Figure 2) [17]. The rate of
progression through the stages can vary based upon several factors, such as underlying disease,
comorbidities, socioeconomic status, genetics, and ethnicity [18].
Because both the MDRD study and CKD-EPI equations are based on serum creatinine,
these equations are not recommended for use in persons with extremes in muscle mass and dietary
protein intake. Additional confirmatory tests can be used if routine test results are uncertain. In the
case of abnormal muscle mass or extreme protein intake, serum cystatin C with or without
creatinine can be used to assess kidney function since serum concentrations of cystatin C are less
influenced by diet and muscle mass than creatinine. Also, abnormal muscle mass, extreme protein
intake, urinary tract infection, heavy exercise, and menstruation may affect the accuracy of urine
albumin to creatinine ratio, in which case albumin excretion rate in a timed urine collection should
be used for assessment [17, 19].
Current United States (U.S.) Preventive Services Task Force guidelines do not recommend
screening for kidney disease in asymptomatic individuals in the general population [20]. However,
per KDIGO guidelines, regular testing is recommended for those in high-risk populations, such as
patients with HTN, DM, CVD, and family history of kidney failure [17].
Treatment of CKD
Once a diagnosis of CKD has been established, both dietary and pharmacotherapy can be
initiated in an effort to slow the progression of further renal damage.
Medications such as angiotensin II receptor blockers (ARBs) and angiotensin-converting
enzyme (ACE) inhibitors work by decreasing the tone or dilating the efferent arteriole, thus
reducing the pressure in the glomerulus. Both drugs are more effective than other antihypertensive
drugs in slowing the rate progression of proteinuric CKD [21].
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Low protein diets (LPD) with or without keto acid analogs have been shown to potentially
delay further kidney damage. Provided there is adequate caloric intake, either a LPD providing
0.55 to 0.60 g of dietary protein/kg ideal body weight/day, or a very LPD providing 0.28 to 0.43 g
of dietary protein/kg ideal body weight/day with additional keto acid analogs to meet protein
requirements (0.55 to 0.60 g/kg body weight/day) is recommended for adults with CKD 3-5 who
are metabolically stable [22-24]. For adults with CKD stages 1-4, diets high in fresh fruits and
vegetables are suggested to improve lipids, body weight, blood pressure, and net acid production.
Additionally, adults with CKD 1-5 (non-dialysis), with or without dyslipidemia, following a
Mediterranean Diet is recommended to potentially improve lipid profiles [25-27].
Interventions are not always effective at delaying the progression of CKD. Consequently,
people with CKD are five to ten times more likely to die prematurely than they are to progress to
ESRD, primarily attributable to cardiovascular disease [28]. In fact, CVD risk is increased at a
GFR of about 75 mL/min and increases continuously as renal function declines [29]. Kidney
diseases were the 9th leading cause of death in the U.S. in 2017 and the 12th most common cause
globally [30, 31]. Furthermore, CKD mortality has increased by 31.7% over the last 10 years,
becoming one of the fastest rising causes of death worldwide [32].
End Stage Renal Disease (ESRD)
Unfortunately, many diagnoses for CKD are made only following chance findings from
screening tests or after symptoms become severe. A patient with a GFR of less than 15
mL/min/1.73m2 is in the final stage of CKD, ESRD Stage 5, at which point renal replacement
therapy (RRT) is considered. Patients requiring RRT must weigh their options to receive either
dialysis (ESRD Stage 5D) or a kidney transplantation (ESRD Stage 5T) for survival [8].
The 2012 KDIGO guidelines suggest that dialysis be initiated when one or more symptoms
or signs attributable to kidney failure are present. Rationale for initiation of dialysis includes
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serositis, acid-base or electrolyte abnormalities, pruritus, inability to control volume status or blood
pressure, progressive deterioration in nutritional status that cannot be managed by dietary
interventions, and cognitive impairment. These signs and symptoms often occur in the GFR range
between 5 and 10 mL/min/1.73 m2 [17].
After determining that RRT is medically indicated, the patient receives evaluation and
counseling to discuss receiving either maintenance hemodialysis (MHD) (in-center or at home),
peritoneal dialysis (continuous or intermittent modalities), or renal transplantation (living or
deceased donor). The majority of patients with ESRD are treated with intermittent (2-3 days per
week) HD to remove fluid volume and kidney wastes.
Whereas dialysis replaces only the non-endocrine functions of the kidney, organ
transplantation replaces both the endocrine and non-endocrine functions. Kidney transplantation
is the most cost effective modality of RRT and provides the best prognosis for survival; however,
demand greatly outweighs the supply of donor kidneys. In 2014, the waiting list for a donor kidney
was 2.8 times larger than the availability of donated organs [33].
United States Renal Data System (USRDS)
Funded directly by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), the United States Renal Data System (USRDS) is a national data system that collects,
analyzes, and distributes information about CKD and ESRD in the U.S. Most of the USRDS
analyses are based from Centers for Medicare & Medicaid Services (CMS) enrollment and claims
data since ESRD is a covered service under Medicare [34].
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Economic Burden of ESRD
There are currently more than 468,000 Americans on dialysis [35]. Total Medicare costs
(excluding prescription drugs) for patients with ESRD accounted for 7% of Medicare fee forservice (FFS) spending, while making up only about 1% of total program enrollment [36].
Traditional and Non-Traditional Cardiovascular Risk Factors
For those patients who do progress to ESRD, mortality due to CVD is reported as 20 times
higher than in the general population. Per the 2018 USRDS, CVD mortality due to arrhythmia
and cardiac arrest comprised 40% of known causes of death among dialysis patients [37]. Most
MHD patients experience CVD complications due to both traditional [38, 39] and non-traditional
risk factors. Traditional risk factors include age, male gender, HTN, dyslipidemia, and smoking.
Non-traditional risk factors, or uremia related factors, include ventricular hypertrophy, chronic
volume overload, anemia, oxidative stress and inflammation, chronic kidney disease mineral bone
disorder (CKD-MBD), and protein energy wasting (PEW) [40, 41].
Oxidative Stress and Inflammation
ESRD patients on MHD suffer from excessive oxidative stress, which has been associated
with an increased risk for CVD and all-cause mortality. The HD procedure itself results in a
significant loss of antioxidants, while the bioincompatibility of dialyzers and dialysate trigger the
production of free radicals [42].
Biochemical indicators of systemic persistent inflammation include the most widely used
inflammatory marker, C-reactive protein (CRP), and cytokines, such as interleukins 6 (IL-6) and
18 (IL-18), and the chemokine monocyte chemoattractant protein-1 (MCP-1) (Figure 3). As a
result from both increased tissue production of inflammatory mediators and their retention due to
inadequate renal removal, MHD patients typically have higher levels of inflammatory markers.
When compared to the general population, serum concentrations of CRP and IL-18 are up to 2- to
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3-fold higher for CKD patients as compared with controls [43, 44]. In addition to inflammation
induced by uremic toxins, obesity, physical inactivity, and smoking also contribute to increased
inflammation [45]. Higher levels of CRP, an acute phase protein produced by hepatocytes, have
been positively associated with mortality in dialysis patients [46, 47].
Higher levels of IL-18, a cytokine primarily produced by Kupffer cells (liver-resident
macrophages) [48], are associated with an increased incidence rate of major adverse cardiovascular
events in HD patients [49]. This proinflammatory cytokine is involved in the process of
atherosclerotic plaque formation [50] and is positively correlated with hospitalization, vascular
injury, and all-cause mortality in HD patients [51].
Elevated levels of IL-6 are commonly observed in HD patients not only due to increased
generation from chronic inflammation, comorbidities, uremic factors, and reduced cytokine
clearance [52], but also due to the dialysis procedure itself [53, 54]. IL-6 has been shown to initiate
endothelial injury thus contributing to increased incidence of CVD in CKD patients [55]. As a
major regulator of acute phase proteins including CRP, albumin, and fibrinogen, IL-6 has been
reported to be a better predictor of CVD complications and mortality than CRP and IL-18 [56-58].
MCP-1 is a chemokine produced by macrophages, endothelial cells, and vascular smooth
muscle cells. This inflammatory cytokine mediates recruitment of monocytes into the
subendothelial space at sites of inflammation. The monocytes differentiate into macrophages,
ingesting lipids to form foam cells, initiating atherosclerosis [59, 60]. MCP-1 is expressed at high
levels in macrophage-rich areas of atherosclerotic plaques, further contributing to the progression
of atherosclerotic disease [61]. In patients with acute coronary syndrome, an increase of MCP-1
levels are correlated with CVD outcomes independent of traditional CVD risk factors [61] and
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with atherosclerotic events and death in persons with CKD [62] as well as associated with an
increased risk for restenosis of arteriovenous fistulas following postangioplasty [63].
Dyslipidemia
Both diet, genetics, lifestyle, and comorbidities can affect lipoprotein composition and
functions. These lipoproteins are an essential group of soluble proteins that combine with and
transport fat or other lipids in the blood plasma. Classified on the basis of density and
electrophoretic mobility, there are seven classes of lipoproteins based on size, lipid composition,
and apolipoproteins: chylomicron, chylomicron remnants, very low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and Lp(a).
Abnormalities in lipoprotein metabolism, associated with a decline in GFR, are one of the
main factors in the pathogenesis of atherosclerosis and CVD in the HD population [64]. As
opposed to hyperlipidemia, it is a dyslipidemic abnormal serum lipid profile that is commonly
observed in ESRD HD patients. The pathogenesis of dyslipidemia is complex and caused by
dysregulation in key enzyme activity and metabolic pathways. Dyslipidemia characteristic of HD
patients includes (1) low HDL cholesterol (HDL-C), which is dysfunctional in its anti-oxidative
and anti-inflammatory roles [65], and a decrease in ApoA-I and ApoA-II levels (two major
apolipoproteins associated with HDL), (2) elevated triglycerides (TAG), (3) relatively normal total
cholesterol (TC), and (4) relatively normal LDL cholesterol (LDL-C), but with an increase in IDL
and small, dense LDL-C and a decrease in larger LDL particles. These LDL and HDL particles
are often modified by the oxidative process. Additional modifications include decreased lecithincholesterol acyltransferase (LCAT), increased cholesteryl ester transfer protein (CETP) activity,
and downregulation of lipoprotein lipase and the LDL receptor [66, 67].
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Small, dense LDL are thought to be more atherogenic than larger LDL particles. Beyond
lipid levels or lipoprotein size, it is believed that lipoprotein particle “cargo” can affect
atherosclerosis development and progression since lipoprotein particles transport many bioactive
lipids, proteins, hormones, and microRNAs. In a 2015 study which compared the molecular
lipidomic profile of LDL between stage 4/5 CKD subjects and non-CKD controls, Reis et. al.
found that while total lipid and cholesterol content was unchanged, lipid subclasses were altered;
LDL particle composition of CKD patients had significantly increased TAG and N-acyltaurines
and significantly decreased phosphatidylcholines, plasmenyl ethanolamines, sulfatides, ceramides,
and cholesterol sulfate [68]. Hu et. al. also found significantly lower levels of sulfatides for HD
patients with CVD compared to those without CVD, and also found no differences in the levels of
TC, HDL-C, and TAG between groups [69]. Many of these lipid species are known to have
beneficial properties, such as the role of plasmalogens as antioxidant agents [70] and the
anticoagulant effects of serum sulfatides [71].
Worse survival rates in ESRD patients have been associated with U-shaped (in Hispanic
MHD patients) [72] or J-shaped (31.8% AA MHD patients) serum HDL-C levels. In the latter
analysis including more than 33,000 HD patients, an increased risk for total and CVD mortality
was reported in patients with HDL-C concentrations < 30 mg/dl and > 60 mg/dl [73].
Using more sophistical techniques, such as density gradient ultracentrifugation, HDL can
be further subdivided into two major subfractions: HDL2-C (larger, more buoyant) and HDL3-C
(smaller, denser), although results have been conflicting about which subpopulations are more
protective [74]. The Jackson Heart Study (JHS) is one of the largest AA community-based,
longitudinal cohort studies evaluating risk factors for CVD development and progression. Among
4,114 non-CKD participants in the JHS study, HDL3-C rather than HDL2-C, was found to be the
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main inverse predictor of HDL-associated risk [75], while in another study of Japanese-Americans,
it was HDL2-C that was more atheroprotective [76]. HDL2-C particles are involved in removing
cholesterol from foam cells [77] and in preventing LDL oxidation [78].
There has been conflicting data regarding the predominant subclass of HDL-C in CKD
patients, which may be due to confounding factors such as ethnicity and lifestyle. Several studies
have reported a shift toward the HDL3-C subclass in ESRD patients on HD [65], whereas others
have reported a decrease in HDL3-C with increasing CKD severity [79]. Nascent HDL particles
are transformed into discoid HDL3 and then should mature into spherical HDL2 enriched with
cholesterol, but because LCAT activity and level is impaired in HD patients, there is more HDL3
and less HDL2 [80]. However, LCAT is also essential for HDL maturation of lipid poor nascent
HDL to lipid rich spherical HDL3 [81].
Recently, the Quantimetrix Lipoprint Lipoprotein Subfractions Testing System was
developed to measure LDL and HDL particle size via gel electrophoresis [82]. Few studies have
reported on results using this system for the CKD population. In a Polish cohort of 115 CKD
patients in CKD stages 2-5D and 25 healthy controls, Rysz-Górzyńska, et. al. reported that large
HDL subfractions were more prevalent in CKD patients versus small HDL subfractions in healthy
subjects [83]. Subfractions obtained by the Lipoprint system have not been correlated to the
subclasses reported in the literature; therefore, it is difficult to compare results from studies using
other separation techniques. The Lipoprint system has been compared to a previously validated
technique, polyacrylamide gradient gel electrophoresis (PGGE), and good agreement was found
to determine LDL size distribution, but not absolute LDL size [84].
Serum non–high-density lipoprotein cholesterol (non–HDL-C), or the difference between
TC and HDL-C, which accounts for the proatherogenic cholesterol content of lipoprotein particles
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(LDL, Lp(a), and TG lipoproteins IDL, VLDL, and CM) has been described as superior to LDLC in CVD risk estimation for the general population [85]. However, a paradoxical association was
found among 51,185 U.S. MHD patients (31.9% AA) with reduced levels of non–HDL-C with
increased CV mortality and poor overall survival. Non-HDL-C levels < 100 mg/dL were
associated with significantly higher mortality risk with the highest all-cause and cardiovascular
mortality being observed in patients with a non-HDL/HDL-C ratio of < 2.5 [86].
While statins have proven effective in improving CV outcomes in the general population,
randomized trials, such as the 4D study (Die Deutsche Diabetes Dialyse Studie) [87] and
AURORA study (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular
Hemodialysis: An Assessment of Survival and Cardiovascular Events) [88], have demonstrated
that there is no benefit from statin therapy in reducing CV events in the ESRD population.
The most recent guideline for management of dyslipidemia in CKD was published in 2003
by Kidney Disease Outcomes Quality Initiative (KDOQI) and is based on the Adult Treatment
Panel III Guidelines from the National Cholesterol Education Program [89], which includes
monitoring LDL-C, HDL-C, TAG, TC levels (using the Friedewald formula) [90]. However, the
KDIGO work group formed to evaluate the KDOQI guidelines developed a new guideline. This
KDIGO group does not recommend using LDL-C as a treatment target given that initiation of
statins is no longer recommended for HD patients; however, discontinuation of statin therapy is
not recommended for patients already receiving these agents at dialysis initiation [91].
Based on the 2003 KDOQI guidelines, CKD patients with dyslipidemia should initiate
therapeutic life-style changes (TLC) if: (1) TAG > 500 mg/dL, (2) LDL-C > 100 mg/dL, and (3)
TAG ≥ 200 mg/dL and non-HDL-C ≥ 130 mg/dL. TLC are shown in Figure 4 and include limiting

14
dietary cholesterol to < 200 mg per day, limiting total fat to 25-35% of total calories, increasing
fiber to 20-30 grams per day, and improving glycemic control [89].
However, it has been demonstrated that there is little benefit in implementing additional
dietary restrictions aimed at lowering lipids superimposed on the standard renal diet. In a small
interventional study published in 2001 which evaluated the effect of trying to comply with
established lipid-lowering recommendations superimposed on the normally prescribed dialysis
diet over 14 weeks (n = 41), it was found that HD subjects decreased saturated fat intakes by 18%
and cholesterol intakes by 16%, but energy intakes also decreased by almost 10%. Additionally,
patients had problems in maintaining compliance with the modified dialysis diets [92].
Protein Energy Wasting (PEW)
PEW, a term proposed by the International Society of Renal Nutrition and Metabolism
(ISRNM), is associated with higher morbidity and mortality in the HD population. ISRNM has
defined PEW syndrome as “the state of decreased body stores of protein and energy fuels.” Loss
of muscle mass has been suggested as the most valid criterion for PEW diagnosis [93], with CKD
induced muscle protein degradation as the main determinant of muscle protein wasting [94]. A
diagnosis of PEW can be made if three of the four criteria are met as outlined in Table 2: namely,
reduced visceral protein stores, reduced BMI or weight loss, reduced muscle mass, and
unintentional low DPI or DEI for at least two months. The pathophysiology of PEW is complex
and attributed to many factors, including malnutrition, aging, metabolic acidosis, uremic toxins,
and inflammation [95]. Impairment of lipid metabolism also contributes to weight loss and
cachexia due to the role of lipids in the production and storage of energy [96]. Measures of muscle
mass are inversely related to systemic inflammatory markers, suggesting that cytokines play an
important role in the development of PEW and muscle catabolism [97]. Chronic inflammation is
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strongly associated with both CVD and PEW in patients on HD [98, 99]. The nexus of protein
energy wasting, inflammation, and atherosclerosis is linked to poor quality of life and increased
morbidity and mortality in ESRD [100].
Sarcopenia
Whereas PEW is characterized by a loss of muscle mass, sarcopenia is defined as (1) low
muscle strength, (2) low muscle quantity or quality, and (3) low physical performance. Patients
with one of these criterion have probable sarcopenia; two criteria indicate a sarcopenia diagnosis,
and in those with all three criteria, sarcopenia is considered severe [101]. The European Working
Group on Sarcopenia in Older People (EWGSOP) published this definition of sarcopenia in 2010
and met again in 2018 to provide clear cut-off points for these criteria (Table 3) [102]. Muscle
strength, which declines more rapidly than loss of muscle, can be measured using a hand grip
dynamometer. This loss of strength has been shown to be profound among healthy AA, who lose
about 28% more muscle strength than whites [103]. Muscle quantity or quality should ideally be
measured using DEXA or BIA, whereas anthropometry, while not as good a measure of muscle
mass, can be used for both screening of sarcopenia and observational study purposes [104].
Whereas “primary” sarcopenia is considered to be age-related, “secondary” sarcopenia
occurs as a result of systemic diseases, such as CKD, with a reported prevalence of 14% to 63%
among ESRD patients [105]. Further contributing to the development of sarcopenia is physical
inactivity and poor nutrition [102].
ESRD Disparities in African Americans
In the U.S., African Americans (AA) suffer a disproportionate burden of ESRD, accounting
for 35% of all dialysis patients, and are 3.7 times more likely to progress to ESRD than whites [8,
106]. Racial disparity of excessive CKD burden in AA results from not only socioeconomic,
lifestyle, and clinical factors, but also from genetic factors. Increased CKD risk in AA is partially
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attributed to higher rates of HTN, DM, and CVD, which may be related to African ancestry, such
as sickle cell trait and variants in the APOL1 gene [107-111]. In fact, sickle cell trait and the
presence of two APOL1 risk alleles may double the risk of CKD [9, 110, 112].
Approximately 13% of the U.S. AA population carries the APOL1 high-risk genotype. It
is theorized that this gene variant developed as an evolutionary mechanism of defense against the
African Trypanosoma parasites, which are transmitted by the tsetse fly and are responsible for
African sleeping sickness or trypanosomiasis. For APOL1 gene variants, the odds of having FSGS
are 17 times greater and for HIV-associated nephropathy, 29 times greater. For AA carrying two
APOL1 risk alleles, the risk for glomerular disease and FSGS occurs earlier and progresses to
ESRD more rapidly [113]. Approximately 20% of AA with an APOL1 risk genotype develop
ESRD; however, much is still unknown about the pathogenesis and phenotypic response to
environment and comorbidities. Clinical interventions for those who carry the APOL1 risk
genotype are currently not available; therefore, APOL1 testing is controversial [114]. However,
testing for this gene variant may correctly identify CKD etiology, as many AA have ESRD caused
by G1 and G2 renal-risk variants in the APOL1 gene, yet the cause of their renal failure is labeled
as hypertension [115].
Social determinants of health, namely socioeconomic status, may also help explain the
increased prevalence of CKD in the AA population. There is a higher proportion of AA living at
lower socioeconomic status with poor access to health care, leading to late diagnosis and treatment
of diseases such as DM and HTN, two major causes of CKD. In the JHS, participants who
experienced the greatest decline in kidney function were older, had lower income, less education,
higher systolic blood pressure, were less likely to have private insurance, and more likely to have
prevalent diabetes and hypertension [116].
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Paradoxically, once on hemodialysis, AA have a survival advantage over whites, likely due
to multiple factors including nutritional status, inflammation, psychosocial status, and genetic
variation [117-122].
Dialytic Removal of Uremic Toxins
HD is the process of removing wastes, such as uremic solutes, and extra fluid from a patient
by filtering their blood through a dialyzer. Uremic solutes can be characterized as belonging to
one of three groups: (1) small water-soluble compounds (< 500 Da), (2) protein bound uremic
toxins (PBUTs) (most < 500 Da except leptin and retinol-binding protein), and (3) middle
molecular weight molecules (≥ 500 Da) [123]. Small water-soluble compounds, such as urea and
creatinine, are easily removed by dialysis and their levels can be used as markers of retention and
removal by the dialysis process [124]. Middle molecules include inflammatory cytokines such as
β-2-microglobulin (reduction ratio ~ 50-60%) [125], tumor-necrosis factor alpha (TNF-α),
interleukin 1β, IL-6 [126]. These middle molecules are more efficiently removed by dialyzers with
larger pore sized (high flux) membranes; however, these membranes do not allow passage of
PBUTs such as p-cresol and advanced glycation end products. Although high flux membranes are
somewhat effective at removing proinflammatory compounds whose retention may be implicated
in CVD risk, middle molecules such as vitamin B12 and insulin can also be lost through the dialysis
process [127]. Newer permeable medium cut-off (MCO) and high cut-off (HCO) membranes allow
for the removal of PBUTs, while reducing the loss of albumin [128].
One of the goals of HD is to remove the excess sodium, phosphorus, and potassium that
has accumulated during the interdialytic period; however, phosphorus removal during the HD
procedure differs from urea or other small molecules. Water molecules bind to phosphorus,
transforming this small molecule into a medium size molecule, hindering passage through the
dialysis pores. Additionally, slow phosphorus transfer rates from the inaccessible intracellular
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space to the accessible extracellular compartment limits removal during dialysis; therefore, serum
phosphorus levels drop quickly during the first hour of dialysis, and then stabilize. An average
dialysis session removes approximately 600-1200 mg of phosphorus [129, 130].
Sodium and Fluid in ESRD
HD patients are at high risk for fluid volume overload between treatments. Large
fluctuations from salt and water intake between HD sessions, termed interdialytic weight gain
(IDWG), result in extracellular volume expansion and elevated blood pressure, which can strain
the cardiovascular system [131]. Greater sodium intake is associated with greater IDWG [132],
blood pressure [131], and mortality among MHD patients [133]. To reduce IDWG, HD patients
are advised to restrict their free fluid intake and reduce dietary sodium intake, which should help
to decrease fluid consumption as well since salt intake leads to ‘‘osmometric thirst’’[134]. IDWG
can be used to assess MHD patient compliance to salt restriction using the following rule of thumb:
a 70 kg anuric patient receiving HD thrice weekly should have a mean IDWG of 1.5 kg; IDWG
exceeding 1.5 kg usually represents an increase in dietary salt intake [135].
Potassium in ESRD
To prevent and manage hyperkalemia, HD patients are advised to follow a low-potassium
diet, which means excluding the consumption of many plant-based foods such as nuts, seeds,
beans, peas, lentils, and fruits and vegetables. Hyperkalemia may result from several non-dietary
factors as well, such as metabolic acidosis or tissue breakdown, which cause a shift of K+ into the
extracellular compartment. Additional contributors to hyperkalemia include prolonged fasting,
medications, and insufficient potassium removal by dialysis. As an adaptation to compensate for
reduced renal elimination, there is 2-3 fold higher colonic potassium excretion in HD patients;
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therefore constipation, reported in ~53% of patients, may also contribute to hyperkalemia [136,
137].
Often asymptomatic, hyperkalemia can present as weakness, fatigue, palpitations, and
cardiac arrhythmias. Hyperkalemia is one of the main reasons for emergency HD, and is the cause
of about 2-5% of deaths among ESRD patients [138, 139].
Phosphorus in ESRD
The balance of hormonal actions that normally regulate systemic phosphorus homeostasis
occur among three organs: the gut (intestinal absorption), the bone (retention or release), and the
kidneys (reabsorption and excretion). This balance becomes dysregulated in ESRD and ultimately
leads to impaired renal excretion and bone resorption of phosphorus, resulting in
hyperphosphatemia [140]. As a result, patients receiving MHD must reduce dietary phosphorus,
and are frequently prescribed phosphate binders to take with meals. However, several factors,
including dietary phosphate load, vitamin D status, and phosphorus bioaccessibility, can influence
intestinal phosphate absorption [141, 142]. Phosphorus in foods are found as food additives
(inorganic) or naturally occurring (organic). Because organic phosphorus from plant protein
sources is stored as phytate, and humans lack the degrading enzyme phytic acid, phosphorus from
plant and legume derived foods is largely inaccessible, with a bioavailability < 40%.
Bioavailability (or bioaccessibility) of organic phosphorus from animal and dairy protein sources
is higher than from plants (about 40-60%). Inorganic phosphate additives found in processed foods
have the highest bioaccessibility, estimated at 90-100% [142-144]. Additionally, the FDA does
not require that manufacturers include phosphorus content on the Nutrition Facts Label [145],
making it difficult for patients to estimate the amount of phosphorus contained in packaged foods.
Per the 2017 KDIGO Clinical Practice Guideline Update for CKD-MBD, it is suggested that the

20
dietitian and other interdisciplinary staff provide education to the patient about phosphate
bioavailability [146].
Treatments for Hyperphosphatemia
Dietary Phosphorus Restriction
Several dietary intervention trials have demonstrated that HD patients who reduce their
intake of foods high in phosphorus or processed foods with added phosphate had significant
reductions in serum phosphorus concentrations [147-149]. However, reducing phosphorus intake
while ensuring adequate protein consumption can be challenging; furthermore, a restricted (and
potentially imbalanced) diet can lead to unfavorable outcomes [150]. Reported nutrient intakes in
HD patients instructed to follow a conventional renal diet has been associated with nutrient deficits
and poor diet quality [151, 152]. Dietary phosphorus restriction limits consumption of many heart
healthy foods, potentially contributing to an atherogenic dietary pattern and resulting in nutrient
deficits of antioxidant vitamins such as vitamins E, C, and carotenoids [153].
Phosphorus to Protein (P/Pro) Ratio
ESRD patients require higher amounts of protein (1.0-1.2 g/kg body weight) to ensure
neutral or positive nitrogen balance. Additionally, 50% of dietary proteins should be of high
biological value (HBV), such as proteins derived from animal sources which provide a complete
amino acid composition to promote conservation of muscle mass [154]. Given that, on average, a
typical diet contains 12-14 mg of phosphorus per gram of protein, an upper limit of 10-12 mg/g
can be used to identify foods with a favorable phosphorus to protein (p/pro) ratio [155]. Animal
proteins can vary in their phosphorus and protein content, for instance, a whole egg contains 6
grams of protein and 86 mg of phosphorus, whereas the egg white contains 3.6 g of protein and
only 5 mg of phosphorus, a p/pro ratio of less than 2 mg/gram [156]. Chicken, pork, veal, trout,

21
and sole have a more favorable p/pro ratio than turkey, salmon, and shrimp. A phosphorus pyramid
(D’Alessandro, et. al., 2015) has been proposed as visual guide for CKD patients to identify foods
based on phosphorus content, p/pro ratio, and phosphorus bioavailability. However, this pyramid
is a guide for both CKD patients and ESRD patients receiving HD, and the “rules” can be
somewhat confusing to follow as many foods with a favorable p/pro ratio are also foods high in
potassium [157].
Phosphate Binders
In conjunction with a low phosphorus diet, phosphate binders are used to bind 250-750 mg
of excess phosphorus per day for dietary phosphorus intakes of 1000 mg/d (restriction) and 1500
mg/d (typical intake), respectively. However, mean phosphorus binding capacity averages
approximately 250-450 mg/day, falling short of what is required to maintain phosphorus balance
[158, 159]. Despite multiple studies linking them to vascular calcification and increased risk of
CVD, calcium based binders are the most commonly prescribed binder as they are well tolerated
and inexpensive [160].
CKD Mineral and Bone Disorder (CKD-MBD)
In CKD Stage 3, patients may begin to develop symptoms of CKD-mineral bone disorder
(MBD), a systemic condition marked by abnormal biochemical tests, vascular calcification, and
alterations in bone morphology. As CKD progresses, patients can develop secondary
hyperparathyroidism (SHPT) as a consequence of the excessive secretion of PTH in response to
decreased calcitriol production, hypocalcemia, and hyperphosphatemia. Pharmacological
treatment options include vitamin D analogs, phosphate binders, and calcimimetic agents;
however, some patients will require a parathyroidectomy [161].
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Vitamin D Analogues
CKD results in vitamin D deficiency (< 20 ng/mL) and insufficiency (20-29 ng/mL) due
to several contributing factors, such as inadequate dietary intake and sunlight exposure, race, sex,
age, obesity, and impaired renal production [162]. The main circulating form of vitamin D is
collectively called calcifediol, which is commonly measured in the plasma to reflect body stores.
The proximal tubular cells within the kidneys are responsible for converting calcifediol into the
active form of vitamin D (1,25-dihydroxyvitamin D), calcitriol, by introducing a hydroxyl group
(-OH) at the 1 position in the second hydroxylation step. The principal action of calcitriol is to
promote calcium absorption from the intestine. Deficiency of calcitriol results in decreased
intestinal calcium absorption, leading to secondary hyperparathyroidism characterized by
hypersecretion of PTH and parathyroid gland hyperplasia. Treatment of secondary
hyperparathyroidism with calcitriol can overly suppress PTH synthesis and produce
hypercalcemia, which may increase risk of vascular calcification [163]. Use of vitamin D analogs
that inhibit PTH gene transcription and parathyroid hyperplasia (identified as vitamin D receptor
activators such as paricalcitol and doxercalciferol) have been associated with improved patient
survival and reduced vascular calcification and inflammatory status [164-166].
Calcimimetic Agents
For those patients who do not respond to phosphate binders and vitamin D analogues for
SHPT treatment, calcimimetic agents, such as Cinacalcet HCl, can be used. As allosteric activators
of the calcium sensing receptor (CaSR) in the parathyroid glands and other tissues, calcimimetics
suppress PTH secretion [167]. These agents can be prescribed in combination with vitamin D
analogues.
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Cardiovascular Complications From Hyperphosphatemia
For ESRD patients on HD, several studies have reported an independent association
between hyperphosphatemia and both cardiovascular and all-cause mortality [168, 169]. Ganesh,
et. al. found a higher mortality risk among HD patients with high serum phosphorus (> 6.5mg/dL)
compared to those with a lower serum phosphorus (≤ 6.5mg/dL) (RR 1.4, p < 0.0005) [170].
Hyperphosphatemia has also been independently associated with coronary artery and aortic
calcification, where each one mg/dL increase in serum phosphorus corresponds to the same
increase in calcification associated with 2 ½ years of receiving dialysis [38, 171].
In a retrospective cohort study of 139,328 HD patients followed from July 2001 to June
2006, investigators found that AA receiving the highest doses of paricalcitol (> 10mg/week) had
a survival advantage over nonblacks who received lower doses or no vitamin D. When compared
to nonblacks, hyperparathyroidism and hypercalcemia, but not serum P, were more prevalent
among the AA patients. As a result, AA-HD patients were more likely to receive higher doses of
vitamin D analogs than nonblacks [172]. In a study published in 2011, researchers conducted 630
bone biopsies in HD patients, finding that white patients demonstrated predominantly low bone
turnover (62%), whereas black patients exhibited mostly normal or high turnover (68%). Given
patients with low bone turnover have abnormal calcium homeostasis [173], and low bone turnover
is associated with vascular calcification [174], differences in mineral metabolism between
ethnicities, such as PTH resistance in the black population, may contribute to the survival
advantage observed in the AA HD population [175].
In addition to better mineral density and bone architecture, AA HD patients have a lower
prevalence of coronary artery and aortic valve calcification and fewer myocardial infarctions as
compared with non-blacks [38, 176-179]. Among non CKD populations, AA (as compared to
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those of European ancestry) have lower levels of calcified atherosclerotic plaque even though they
experience more severe traditional CVD risk factors such as HTN, poor glycemic control, and
higher prevalence of dyslipidemia with higher overall mortality rates from CVD [180-182].
Renal Diet and Antioxidant Intake
Although both the dialysis procedure and pharmacological treatments are effective at
reducing the uremic toxin load, restrictions on dietary phosphorus and potassium are often required
to maintain serum levels within physiological range [183]. In an effort to avoid foods high in
phosphorus and potassium, limits are placed on the quantity of certain fruits, vegetables, nuts,
legumes, dairy, and whole grains that can be eaten [184]. This reduced consumption of foods
naturally rich in phytochemicals, such as carotenoids and polyphenols, can result in a loss of
benefit from the antioxidant and anti-inflammatory activities associated with their intake [185].
Dietary Patterns in ESRD
Nutrition research has shifted focus from single nutrients or foods to dietary pattern
analysis, which describes the overall diet and their combination, frequency, and quantity with the
association on health risk [147, 186-188].
Most studies which examine dietary patterns focus on prevention of disease progression. It
has been found that dietary patterns high in fat and sugar, considered “unhealthy”, are associated
with increased risk and progression of comorbidities such as heart disease, diabetes, and CKD
[189-191], whereas healthier diet patterns, which include higher intakes of vegetables, fruits,
legumes, nuts, whole grains, fish, and low-fat dairy, and lower intakes of red and processed meats,
sodium, and sugar-sweetened beverages, have been associated with a lower incidence of CKD
[26].
Only a few dietary pattern studies have focused on the HD population. Sualeheen, et. al,
found that for Malaysian HD patients, dietary patterns reflective of home-based, healthier food
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choices were associated with better nutritional status [192]. In the Japan Dialysis Outcomes and
Practice Patterns Study (JDOPPS), an “unbalanced” dietary pattern was associated with increased
CVD related hospitalization and all-cause mortality [193]. However, in a European cohort of
patients enrolled in the DIET-HD study, a dietary pattern high in fruits and vegetables was not
associated with a cardiovascular or all-cause mortality benefit [194]. It is worth noting that the diet
analyses used in both the JDOPPS and DIET-HD studies were based on self-reported food
frequency questionnaires, which did not account for differences in portion sizes.
Two main analytical approaches used to identify dietary patterns in nutritional
epidemiology are à priori (hypothesis-driven) and à posteriori (data-driven) methods [195, 196].
À priori methods are based on indices of diet quality or nutritional health defined scores and assess
the extent to which a subject complies with the predefined dietary pattern, whereas à posteriori
methods use multivariate statistical techniques to derive dietary patterns empirically based on the
actual diet in a specific population [197].
À Priori Methods
À priori methods are usually based on dietary guideline definitions and employ a scoring
algorithm to determine participant adherence. Examples of à priori dietary patterns include the
Mediterranean Diet Score [198], the Healthy Eating Index [199], and the Dietary Inflammatory
Index (DII) [200]. These methods are based on indices of diet quality or presence or absence of
certain foods or nutrient characteristics used to calculate a score, which is then operationalized as
an explanatory variable [201].
The DII is an à priori method developed by researchers at the University of South Carolina
to provide a means for estimating the overall inflammatory potential of the diet [202]. The DII is
based upon the inflammatory properties of macronutrients, vitamins and minerals, flavonoids, and
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other bioactive compounds and includes evidence from both in vitro and in vivo experiments, as
well as several study designs, nutritional assessment methods, and populations. The DII differs
from other epidemiologic dietary indices, such as DASH or HEI, which are based on adherence to
dietary guidelines or recommendations [203].
The current DII uses a scoring algorithm standardized to the distribution of dietary intake
from representative populations around the world of 45 food parameters based on their
inflammatory effect on six biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α and C-reactive protein).
Higher DII scores indicate more pro-inflammatory diets, whereas negative values reflect antiinflammatory diets, with scores potentially ranging from +7.98 (pro-inflammatory) to -8.87 (antiinflammatory) [202].
As chronic low-grade inflammation is both a consequence and contributor to CKD [204]
and diet has the potential to modulate inflammation [205], assessing the DII for HD patients may
provide valuable insight into the potential inflammatory contribution from foods consumed in a
typical renal diet.
À Posteriori Methods
Two commonly used à posteriori methods are (1) cluster analysis, which separates
individuals into mutually exclusive, non-overlapping groups based on differences in mean dietary
intake [197] and (2) factor analysis, which reduces data based on correlation or covariance matrices
into components, factors, or patterns based upon relationships between dietary items [206]. These
methods are driven by the underlying dietary data and summarize the effect of the overall diet.
Rather than assessing the relationship of health with single nutrients, using dietary patterns reflects
the synergistic impact that habitual patterns of foods eaten in combination has on health outcomes.
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Cluster analysis is a common à posteriori method used to assess dietary patterns through a data
reduction technique [207].
Patient Reported Outcome Measures (PROMs)
Diet Data
In the clinical setting, formal methods of dietary assessment are seldom used, due to time
constraints and patient loads. However, in research, either food frequency questionnaires or dietary
recalls (24 hour, 2 or 3 days) are used to collect diet data. With diet recalls, issues can arise from
underreporting usual energy intake which can include both under-recording and undereating. This
former group is also referred to as implausible low energy intake (EI) or “low-energy reporters”.
In under-recording, participants either fail to report all the items consumed or underestimate the
amounts reported leading to a discrepancy between reported EI and measured energy expenditure
(EE). In undereating, participants eat less than required to maintain body weight, which is
accompanied by a decline in body mass [208].
To account for under-recording, several methods are available to remove biologically
implausible intake reports before drawing conclusions about diet associations. Some methods are
crude, such as excluding only those participants reporting EI extremes, whereas others take into
consideration activity level and employ cutoffs using statistical adjustments that account for
within-participant variation in EI and total energy expenditure (TEE) [209].
Quality of Life (QOL)
The Kidney Disease Quality of Life Short-Form 36-items survey (KDQOL-SF36™) is a
validated self-reported questionnaire developed to assess quality of life for ESRD patients on HD
[210]. As part of its conditions for coverage, CMS mandated that ESRD facilities conduct an
annual assessment of health related quality of life (HRQOL) on all dialysis patients [211, 212].
KDQOL™-36 was chosen as the HRQOL required survey by The National Quality Forum as the
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tool of choice. Dialysis facilities are required to assess patients’ HRQOL within 4 months of
initiating dialysis, and annually thereafter [213]. The survey is comprised of five subscales
calculated separately: 1) SF-12 physical component summary (PCS), 2) SF-12 mental component
summary (MCS), 3) burden of kidney disease, 4) symptoms of kidney disease, and 5) effects of
kidney disease. Subscale scores range from 0 to 100, with lower scores indicating poor selfreported QOL [214]. Independent of demographic and comorbidity factors, lower PCS and MCS
subscale scores have been associated with higher risk of hospitalization and death in HD patients.
Several studies have found SF-12 PCS to be the strongest prognostic subscale [215, 216].
Additionally, lower PCS and MCS subscale scores were found to be positively correlated with
both Body Mass Index (BMI) and body fat percentage [217]. Common symptoms of ESRD include
lack of energy or fatigue, pain, drowsiness, pruritis, dry skin, shortness of breath, swelling of the
legs and arms, worrying, nervousness, irritability, and sadness. In the month preceding death,
symptom burden has been reported to be the greatest, and persistent fluid overload and lethargy
have been found to be indicators of near death [218].
Appetite Diet and Assessment Tool (ADAT)
A 44 question appetite diet and assessment tool (ADAT) was initially developed for the
National Institutes of Health Reduction of Morbidity and Mortality in HD Patients Pilot study to
evaluate appetite and factors affecting dietary intake [219]. The first three questions from the
ADAT were later used to determine whether appetite had changed over time in the treatment
groups for patients participating in the Hemodialysis (HEMO) study. It was found that poor
appetite was associated with increased hospitalization rates among HD patients [220].
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Biological Outcome Measures
Biochemical Markers
Per CMS guidelines, HD facilities must evaluate factors associated with anemia (i.e.
hemoglobin, hematocrit, and iron stores), evaluate nutritional status by monitoring albumin levels
and body weight at least monthly, and assess the adequacy of the patient’s dialysis prescription at
least monthly to meet a minimum Kt/V goal of at least 1.2 [221]. In addition to these federal
requirements, KDOQI guidelines recommend monitoring serum calcium, phosphate, and PTH for
the diagnosis, evaluation and treatment of CKD-MBD. [222]. Additional markers, such as serum
creatinine levels, may be monitored. As a breakdown product of creatine phosphate in muscle,
high levels of creatinine (in HD patients without residual renal function) may serve as a surrogate
of muscle mass and have been associated with better survival predictability [223, 224].
Anthropometry
Anthropometric measurements, such as height, weight, BMI, body circumferences, and
skinfold thickness are quantitative measurements used to assess body composition. Although
obesity is associated with both a higher risk of developing CKD [225] and increased CV mortality
in the general population [226], once a patient develops CKD, overweight and obesity are
paradoxically associated with a survival benefit, irrespective of race [227-229], with the most
prominent survival advantage among AA MHD patients compared to Hispanics and non-Hispanic
Whites [228, 230]. This ‘obesity paradox’ may be related to uremic toxin sequestration in fat mass,
lipoprotein defense against circulating endotoxins, reduced prevalence of protein energy wasting
(PEW), increased micronutrient intake, attenuation of inflammation, additional “reserve” during
times of illness, or an interplay of several factors [231, 232].
Even though both higher fat mass and muscle mass are associated with improved survival,
muscle mass appears to be superior to fat mass in providing greater mortality benefits [233]. In
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comparison to fat mass gains, achieving muscle gains (or preventing losses) is more difficult,
requiring both resistance exercise along with a high protein intake of HBV [234]. The survival
benefit observed in AA ESRD patients may be related to muscle mass, which is higher in AA than
in Whites [233, 235].
Given treatments aimed at traditional risk factors such as obesity, hypertension [236] and
hypercholesterolemia [88] have not been shown to reduce CVD morbidity and mortality in ESRD
patients, and maintaining lean body mass has been shown to confer a survival benefit, dietary
intervention efforts focused on this latter goal may be efficacious.
Measuring Fat Mass and Lean Body Mass
BMI cannot distinguish between fat mass and lean body mass (LBM), which represents
muscle mass and somatic protein stores in HD patients [224]. Evaluating the combination of both
fat tissue index and skeletal muscle mass index has been reported to more accurately predict allcause mortality when compared with BMI [237]. Several body composition methods are available,
such as dual-energy X-ray absorptiometry (DEXA), the gold standard for fat mass assessment, and
bioimpedance analysis (BIA), a less expensive and more portable option to assess fat and fat free
mass [238]. Indirect measurements, such as mid-arm muscle circumference (MAMC) and hand
grip strength (HGS) can serve as a surrogates for LBM in HD patients and have been widely used
in epidemiological studies [223].
NKF Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
Published in the American Journal of Kidney Diseases (AJKD), The National Kidney
Foundation (NKF) produces evidence-based clinical practice guidelines through the NKF Kidney
Disease Outcomes Quality Initiative (NKF KDOQI)™ [239] and published the most recent
nutrition guidelines in 2000 [154]. Current nutrition guidelines for HD patients per the 5th Edition
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Pocket Guide to Nutrition Assessment of the patient with Chronic Kidney Disease are outlined in
Table 1 [240].
KDOQI, in collaboration with the Academy of Nutrition and Dietetics (AND), is in the
process of updating its Clinical Practice Guideline on Nutrition in CKD which is still undergoing
revisions based on public commentary [239]. The draft, available for review, introduces changes
to several key guidelines and an expanded methodology used in the creation of the new guidelines.
Both a workgroup of 15 members, including physicians, Registered Dietitians, researchers, and
methodologists with expertise in the renal nutrition field, and an evidence review team worked
together to develop these updated CKD specific nutrition guidelines by following the AND’s
systematic review methodology. Proposed changes to the new guidelines for HD patients include
a slight reduction in dietary energy intake (DEI) and dietary protein intake (DPI) ranges, without
mention of the specific need for high biological value [25].
The importance of diet to clinical outcomes is of such significance that CMS has mandated
that every dialysis patient should receive individualized comprehensive assessment and treatment
by a renal dietitian [221]. With advanced kidney disease, patients may become deficient in B
vitamins, iron, vitamins C and K, zinc, copper, selenium, and calcitriol. Inadequate micronutrient
intakes can contribute to the higher burden of oxidative stress, inflammation, and CVD observed
in the ESRD population [241]. Conversely, excessive intakes of phosphorus, potassium, and fluid
are also associated with increased risks of cardiovascular morbidity and mortality [138, 242, 243].
Nutrient guidelines are often communicated to patients using written materials which highlight
foods to avoid or include based on sodium, potassium, and phosphorus content. Recently, attention
has shifted from restricting all high phosphorus containing foods to limiting those foods high in
inorganic, and thus highly bioavailable, phosphorus [157, 184, 244].
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The Role of the Registered Dietitian Nutritionist (RDN)
Registered Dietitian Nutritionists (RDNs) must adhere to a code of ethics which requires
using current evidence based nutritional guidelines. Patient-client centered care is a major tenet of
the interactive-integrative paradigm. The RDN utilizes both information obtained from the patient,
which not only includes access to food, barriers (financial, food insecurity, and motivational),
family support, reported intake, and self-efficacy for behavior change, with clinical history to
guide medical nutrition therapy (MNT) [245]. When discussing with the patient foods that should
either be included or excluded from the diet, several foods may fall into a “grey” area. For example,
whole grains, legumes, fruits, and vegetables provide good sources of fiber which can help
alleviate constipation, yet many of these foods are high in phosphorus and potassium [246].
Controversial Foods
The egg exemplifies a type of “controversial” food for the HD patient, as it provides a
readily available, inexpensive source of protein, yet is high in phosphorus (albeit organic), and a
rich source of cholesterol. Further research into the current recommendations for eggs in the CKD
population revealed a lack of both formal guidelines and published studies; therefore, we
completed the first published review (Tallman, et. al, 2018) examining egg intake in CKD [247].
Despite several meta-analyses suggesting that higher egg consumption of up to one egg per
day is not associated with increased CVD risk in the general population [248, 249], egg intake
remains controversial, notably for individuals with comorbidities, such as diabetes and ESRD, as
CVD risk and consumption of whole fresh eggs remains inconclusive for these populations [250,
251].
The egg yolk contains bioactive compounds, including lutein, zeaxanthin, and vitamin D,
nutrients which may be beneficial for HD patients. However, the yolk is also a rich source of both
cholesterol and phosphorus. Whole egg consumption in context of the entire diet, particularly when
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compared to foods an egg may replace, such as processed foods or high sugar products, should be
examined given individuals do not consume nutrients or foods in isolation.
Optimal Renal Diet
Traditionally, nutrition research has focused on health outcomes with individual nutrients
and foods, such as eggs and CVD risk; however, using this approach has several limitations. First,
people eat meals which contain a variety of ingredients with complex combinations of nutrients
that may act synergistically. Second, the effect of a single nutrient may be difficult to discern, but
the cumulative effects of several nutrients in a dietary pattern may be large enough to detect. Third,
intercorrelation among some nutrients makes it difficult to examine their separate effects. These
limitations can be overcome by using a dietary pattern approach to examine how foods and
nutrients are eaten in combination [187].
Nutritional approaches to improve outcomes for ESRD patients on HD have evolved over
time and reflect technological advances in RRT [252]. At the same time, nutritional epidemiologic
studies have shifted to using a dietary pattern analysis to examine associations with health
outcomes. The changes proposed by the updated KDOQI guidelines reflect this paradigm shift.
The current draft includes a statement on dietary patterns suggesting a Mediterranean diet for adult
CKD 1-5 (non-dialysis) patients to improve lipid profiles. Presently, there are no suggested
patterns for AA ESRD patients receiving HD.
Specific Aims
Based on the preceding sections, the long term goal of research in this field is to optimize
nutrition regimens in HD patients to improve health outcomes.
The central hypothesis is that renal dietary guidelines need to be targeted based on patientcentered dietary patterns. The rationale for this research is that once specific dietary patterns are
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identified, cross-sectional studies can be designed to evaluate health outcomes. The goal of this
Ph.D. project is to identify and document dietary patterns in African American HD patients.
To test my hypothesis the following specific aims were established:
Specific Aim One: To Characterize the Nutrition and Health Status in a Cohort of African
American Maintenance Hemodialysis Patients.
•

Specific Aim 1A: To Characterize the Overall Study Population.

•

Specific Aim 1B: To Assess Protein Energy Wasting (PEW), Dyslipidemia, and
Inflammation in the Study Population.

•

Specific Aim 1C: To Evaluate Phosphorus to Protein Ratio and Dietary Inflammatory
Index From the Derived Nutrition Information.

Specific Aim Two: To Evaluate the Association of Cluster Analysis Derived Dietary Patterns with
Health Outcomes in a Cohort of African American Maintenance Hemodialysis Patients.
Specific Aim Three: To Assess the Effect of Nutrition and Health Status in a Cohort of African
American Maintenance Hemodialysis Patients on Mortality.
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Tables and Figures
Table 1: Nutrient Recommendations for HD Patients
Protein (g/kg)
1.2 stable
1.2-1.3 acutely ill or PEW
Energy (kcals/kg)
30-35 ≥ 60 years
35 < 60 years
Sodium (mg/d)
750-2000
Potassium (mEq/d)
Up to 70-80 mEq/d;
adjust to serum levels
Fiber g/d
20-25
Fluids cc/d
750-1500
Calcium mg/d
≤ 1000; maintain serum calcium WNL
Iron mg/d
Individualized
Magnesium mg/d
200-300
Phosphorus mg/d
10-17 mg/kg/d
Selenium mcg/d
NA
Zinc mg/d
15
Daily Vitamin Supplementation Recommendations
Ascorbic Acid mg/d
75-90
B1 (Thiamine) mg/d
RDA
B2 (Riboflavin) mg/d
RDA
B6 (Pyridoxamine) mg/d
10
B12 (Cobalamin) μg/d
RDA
Biotin μg/d
RDA
Folic Acid mg/d
1
Niacin mg/d
RDA
Pantothenic Acid mg/d
RDA
Vitamin A μg RE/d
None
25-hydroxy Vitamin D IU
Calcitriol, vitamin D analogs, calcimimetics
based on serum calcium, phos
Vitamin E (IU)
15
Vitamin K μg/d
With antibiotic therapy, 10 mg/d
mg = milligrams; RDA = recommended dietary allowance
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Table 2: Criteria for the Clinical Diagnosis of PEW in CKD
Serum Chemistry Serum albumin < 3.8 g/dla
Serum prealbumin (transthyretin) < 30mg/dla
Serum cholesterol < 100mg/dla
BMI
BMI (edema-free) < 23
Unintentional weight loss over time: 5% over 3 months or 10% over 6
months
Total body fat percentage < 10%
Muscle Mass
Reduced muscle mass 5% over 3 months or 10% over 6 months
Reduced mid-arm muscle circumference areab (reduction > 10% in
relation to 50th percentile of reference population)
Creatinine appearancec
Dietary Intake
Unintentional low dietary protein intake < 0.80g/kg/day for at least 2
months
Unintentional low dietary energy intake < 25kcal/kg/day for at least 2
months
Adapted from Obi, et. al. Curr Opin Clin Nutr Metab Care, 2015 [96].
At least three of the four listed categories along with at least one test in each of the selected categories must be
satisfied for the diagnosis of kidney disease related PEW. Each criterion should be documented on at least three
occasions, preferably 2–4 weeks apart.
Not valid in abnormally great urinary or gastrointestinal protein losses, liver disease, or cholesterol-lowering
medicines
b
Measured by a trained anthropometrist.
c
Creatinine appearance is influenced by both muscle mass and meat intake.
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Table 3: EWGSOP2 Sarcopenia Cut-Off Points
Test
Cut-off points for men
Cut-off points for women
Sarcopenia cut-off points for low strength by chair stand and grip strength
Grip strength
< 27 kg
< 16 kg
Chair stand
> 15 s for five rises
Sarcopenia cut-off points for low muscle quantity
ASM
< 20 kg
< 15 kg
ASM/height2
< 7.0 kg/m2
< 5.5 kg/m2
Sarcopenia cut-off points for low performance
Gait speed
≤ 0.8 m/s
SPPB
≤ 8 point score
TUG
≥ 20 s
400 m walk test
Non-completion or ≥ 6 min for completion
Table adapted from Sarcopenia: revised European consensus on definition and diagnosis [102]. ASM: Appendicular
Skeletal Muscle Mass; SPPB: Short Physical Performance Battery; TUG: Timed-Up and Go test
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Figure 1: Anatomy of the Kidney and Nephron (adapted from National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases) [3]
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Persistent Albuminuria Categories
Description and Range

GFR Categories (mL/min/1.73m2)
Description and Range

Prognosis of CKD by GFR
and Albuminuria Categories:
KDIGO 2012

G1

Normal or high

≥ 90

G2

Mildly decreased

60-89

G3a

Mild to moderately
decreased

45-59

G3b

Moderately to severely
decreased

30-44

G4

Severely decreased

15-29

G5

Kidney failure

< 15

A1

A2

A3

Normal to
mildly
increased

Moderately
increased

Severely
increased

< 30
mg/g

30-300
mg/g

> 300
mg/g

Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased
risk; Orange: high risk; Red, very high risk.
Figure 2: Prognosis of CKD by GFR and Albuminuria Category [17]
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Figure 3: IL-18 Pathway and Downstream Cytokines
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Figure 4: Therapeutic Lifestyle Changes (TLC) for Adults With Chronic Kidney Disease From
KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease [89]
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CHAPTER 2: METHODOLOGY
General Study Design
Data was collected from subjects participating in the Palm Tocotrienols in Chronic
Hemodialysis (USA) (PATCH) Study (NCT02358967), a randomized double-blind, placebocontrolled trial evaluating the effects of daily supplementation with 300 mg of a vitamin E
tocotrienol-rich fraction (TRF) on markers of inflammation, oxidative stress, and blood lipids in
MHD patients. The PATCH clinical trial is a multinational cohort of patients receiving MHD and
includes a Malaysian arm (NCT02913690) (Figure 5).
The purpose of this study is to analyze the impact of dietary patterns with health outcomes
in African American patients receiving MHD. To achieve this goal, a secondary analyses of data
collected from 135 subjects participating in the PATCH Study was conducted. Given the small
percentage of non-African American subjects (5%) in the cohort, only AA subjects were
considered for inclusion in this secondary study. Baseline data was used for all analyses, with the
exception of diet data, for which the average of six 24-hr dietary recalls taken during the duration
of the study were used. 27 AA subjects for whom all six 24-hr dietary recalls were deemed
implausible were screened out, and 101 AA subjects with plausible dietary intake records were
included in all subsequent analyses.
Criteria for study participation included: (1) Patient is willing and able to give informed
consent for participation in the trial (2) Male or female, aged 18 years and above and undergoing
chronic hemodialysis treatment for more than 3 months (life expectancy > 1 year). (3) Able and
willing to comply with all trial requirements. (4) Willing to allow his or her Physician,
Nephrologist, or General Practitioner and consultant, if appropriate, to be notified of participation
in the trial.
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Exclusion criteria included (1) Participants who have participated in another research trial
involving an investigational product in the past 12 weeks. (2) History of functional kidney
transplant 6 months before study entry; anticipated live donor kidney transplant over the study
duration. (3) Participants who are taking vitamin E- containing supplements > 60 IU/d during the
past 30 days. (4) History of poor adherence to hemodialysis or medical regimen. (5) Participants
who are currently on active treatment for cancer, excluding basal cell carcinoma of the skin. (6)
Participants who have been diagnosed with HIV/AIDS and/or on anti-HIV therapy. (HIV
seropositivity is not an exclusion criterion). (7) Patients taking anti-inflammatory medication,
except aspirin < 325 mg/d, over the past 30 days. (8) Female participants who are pregnant,
lactating or planning pregnancy during the course of the trial. (9) Participants who are receiving
nutritional support (i.e. enteral and intra-venous route). (10) Patients using a temporary catheter
for dialysis access at baseline or patients receiving a graft/fistula within the 6-month study period.
(11) More than two hospitalizations within the last 90 days or one hospitalization within the 30
days preceding enrollment. (12) Any other significant disease or disorder which, in the opinion of
their nephrologist, may either put the participants at risk because of participation in the trial, or
may influence the result of the trial, or the participant's ability to participate in the trial.
135 subjects were enrolled from five hemodialysis clinics in the metro Detroit, Michigan
(USA) area and randomly assignment to receive either treatment or placebo. Three DaVita clinics
(Redford, Highland Park, and Kresge), two Henry Ford clinics (Fairlane and West Pavilion) and
one private clinic, Great Lakes Dialysis, participated in the study. Participants were enrolled in the
study for 15 months (12 month treatment period, followed by a 3 month washout period with 3
month follow-up) and visited quarterly. Dates of enrollment spanned from June 2017 to February
2018 with all study procedures completed by April 2019.

44
Ethics and Human Subject Issues
The study was approved by the ethics boards of participating dialysis units and Wayne
State University’s Institutional Review Board. All subjects provided informed written consent.
Informed consent was obtained by either the Nephrologist or the Registered Dietitian at each clinic
site. Study participants received $15 compensation monthly for the first 12 first months of
enrollment while receiving capsules, and an additional $20 for completing the entire study (i.e.
participating in the 15 month follow-up visit).
Capsule Distribution
At the Great Lakes and DaVita clinics, participants were provided capsules by the nursing
staff during dialysis days (three days per week) under direct observation, and were responsible to
self-administer capsules on non-dialysis days. At the two Henry Ford Clinics, participants were
responsible for capsule self-administration on all days. A member from the PATCH clinical team
was responsible for distributing the capsules to the clinic staff for disbursement, and solely
responsible for disbursing participant compensation (in the form of a gift card) and obtaining the
participant’s signature as proof of receipt.
Collection and Handling of Blood Samples
Two 10 mL vacutainer tubes with Ethylenediaminetetraacetic acid (EDTA) and lithium
heparin preservatives (BD, Franklin Lakes, NJ, USA) were labeled with the patient name and
instructions on pre-dialysis blood draw and delivered to the floor charge nurse. Clinic dialysis
technicians collected pre-dialysis blood samples from patients prior to their dialysis session and
placed the samples into sealed specimen bags under refrigeration. A member from the PATCH
clinical team relabeled the tubes with the WSU identification number, packed the samples on ice,
and transported them to a Wayne State University laboratory within two hours of collection.
Samples collected in the EDTA tubes were designated for analyses of lipid profiles while lithium
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heparin tubes were used for analyses of inflammatory markers. Plasma was separated by
centrifugation at 3500 rpm for 10 minutes at 4°C (GS-6KR Centrifuge, Beckman-Coulter, USA)
and aliquots were stored at -80°C until further analysis.
Patients Demographics and Biochemical Data
A case report form (Appendix A) was used to collect data provided by the HD clinic.
Demographic data, recent laboratory values, diagnoses, dialysis vintage, prescribed medication,
hemodialysis prescription, and measures of dialysis adequacy were obtained from both the medical
chart and from clinic staff via printouts from the electronic medical record. Additional information
that was not available in the clinic chart was obtained from the patient. The data from these records
were transposed by hand to the case report form to comply with the Health Insurance Portability
and Accountability Act of 1996 (HIPAA) Privacy Rule to protect the patients’ personal health
information (PHI). All data was then entered manually into an excel program, using a Wayne State
number to identify each patient.
Patient Reported Outcome Measures (PROMs)
24-hour dietary recall
Six 24-hour dietary recalls (Appendix A) taken on non-dialysis days were collected in
person quarterly over a 15-month time period [207, 253] using the U.S. Department of Agriculture
(USDA) five-pass method [254]. Household measuring cups and spoons were used as a visual aid
to assist subjects in gauging portion sizes. All 24-hr dietary recalls were collected by a single
Registered Dietitian to eliminate inter-observer variation. Interviews were conducted at each clinic
during the dialysis session. The dietary recalls were then manually entered into the Food Processor
SQL software package (version 11.2, 2016, ESHA Research, Salem, OR) to calculate nutrient
analyses and to generate reports for all collected recalls (Appendix C).
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Implausible Dietary Intake Reports
To reduce the effect of confounding from physiologically implausible reported energy
intakes (rEI), dietary reports from both over and under-reporters were screened out [255]. Using
the method introduced by McCrory, et al., which accounts for within-subject errors in rEI and
predicted total energy expenditure (pTEE) without estimation of physical activity level, a 2standard deviation cutoff was used to classify 24HR recalls less than 56% or more than 144% of
estimated energy needs as implausible using the following equation.

± 2𝜎 = √

2
𝐶𝑉𝑤𝐸𝐼
2
2
+ 𝐶𝑉𝑤𝑝𝑇𝐸𝐸
+ 𝐶𝑉𝑡𝑚𝑇𝐸𝐸
𝑑

where 𝐶𝑉𝑤𝐸𝐼 is the within-subject coefficient of variation in energy intake, d is the number of days
of energy intake measurement, the pTEE prediction equation as follows:
𝑝𝑇𝐸𝐸 = 7.377 − (0.073 × 𝑎𝑔𝑒) + (0.0806 𝑥 𝑤𝑒𝑖𝑔ℎ𝑡) + (0.0135 × ℎ𝑒𝑖𝑔ℎ𝑡)
− (1.363 𝑥 𝑠𝑒𝑥),
where age is in years, weight is in kg, height is standing height in cm, and sex is 0 for men and 1
for women. The 𝐶𝑉𝑤𝐸𝐼 was calculated at 25.7% with 6 days (d) of energy intake measurements.
A value of 17.7% was used for 𝐶𝑉𝑤𝑝𝑇𝐸𝐸 , which is the coefficient of variation (CV) of pTEE, and
8.2% was used for 𝐶𝑉𝑡𝑚𝑇𝐸𝐸 , which is the within-person CV of measured TEE which takes into
account measurement error and biological variation in TEE. These latter two values are constants
derived from previous studies [209, 256]. Edema-free adjusted body weight (aBWef) was used for
patients whose weight was < 95% or > 115% of standard body weight (SBW) using the following
equation [154, 257]:
𝑎𝐵𝑊𝑒𝑓 = 𝐵𝑊𝑒𝑓 + [(𝑆𝐵𝑊 − 𝐵𝑊𝑒𝑓 ) 𝑥 0.25],
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where SBW is defined as the 50th percentile of body weight for gender, height and body frame
size determined from the National Health and Nutrition Examination Survey (NHANES) II data
[258]. After removing 27 subjects for whom all six dietary recalls were considered implausible, a
total sample size of n = 101 was used for all subsequent analyses.
Dietary Inflammatory Index
29 food parameters were available from all plausible dietary intake records, including mean
daily intakes of energy, protein, carbohydrate, fat, saturated fat, polyunsaturated fatty acids
(PUFA), monounsaturated fatty acids (MUFA), omega-3 fatty acids, omega-6 fatty acids, trans
fats, cholesterol, vitamin A, beta-carotene, vitamin E, vitamin B1, vitamin B2, niacin, vitamin B6,
vitamin B12, folic acid, vitamin C, vitamin D, magnesium, iron, zinc, selenium, fiber, alcohol, and
caffeine were used for the calculation of DII. The inflammatory effect scores used for calculation
of the DII is shown in Table 4. A z-score for each food consumed was calculated by subtracting
the “standard global mean” from the amount reported and dividing this value by the standard
deviation. To minimize the effect of “right skewing”, this value was then converted to a centered
percentile score. The centered percentile score for each food parameter was then multiplied by the
respective food parameter effect score to obtain a food parameter-specific DII score for a given
participant. The overall DII score for each subject was calculated by summing all food parameter
DII scores for that subject; the mean DII scores from all plausible recalls were used in subsequent
analyses. DII scores were dichotomized and treated as an independent categorical variable from
which to compare differences in higher and lower DII with inflammatory markers, clinical
chemistry, and dietary intake.
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Cluster Analysis Derived Dietary Patterns
A flowchart depiction is shown in Figure 6. Using Microsoft excel, for each subject, foods
consumed at each timepoint for all plausible intake records were compiled. Household
measurements were converted to gram weights for all foods using the USDA Nutrient database,
nutrient analysis listed on web sites by restaurants, fast food establishments, or manufacturer
provided information. The gram weights were cross checked with the nutritional analysis output
from ESHA Food Processor SQL software package. All individual foods recorded for all subjects
were combined into one excel sheet and sorted by name to identify core food groups based on
conceptual and compositional similarities. Identifying groups of food items requires an
understanding of food preparation practices, food composition, and patterns of consumption. For
instance, breads were subdivided into yeast breads and quick breads, since chemical leavening
agents are used in the latter product, and these agents are sources of inorganic phosphorus. Thirtythree food groups were identified. A template was created to (1) sort all foods recorded from the
24-hr dietary recalls into each of the respective thirty-three food groups by gram weight and (2)
calculate the mean intake of each food group per subject. Frequency distribution was calculated
for all food groups to determine if any food group was consumed with less than a 5% frequency.
Since no foods groups met that criteria, all thirty-three food groups were converted to percent
contribution of total daily energy (%TE) intake [259]. A cluster analysis was performed using the
k-means algorithm, a nonhierarchical clustering method which classifies participants into nonoverlapping groups based on Euclidean distance, to obtain dietary patterns. A two cluster
membership was found to provide the optimal solution. Convergence was achieved after seven
iterations with a membership of n = 47 in cluster 1 and n = 54 in cluster 2. ANOVA revealed
significant differences between groups for six variables (α = 0.10). A second cluster analysis was
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conducted with only the six significant variables. A Chi-Square test of homogeneity was conducted
to determine discordant pairs. Percent concordance between all variables and all significant
variables was 84.2% ( = 0.674); therefore, all variables were included in the dietary pattern
analyses.
Statistical Analyses
Differences between groups were compared according to data distribution using t test or
Mann-Whitney U test for continuous variables and Pearson chi-square test for categorical
variables. For all tests, the level of significance was set as p < 0.05. All analyses were performed
using SPSS (Version 25, SPSS Inc., Chicago, Illinois, USA).
Appetite and Diet Assessment Tool (ADAT)
Responses were recorded to the three question ADAT for all subjects participating in the
PATCH study on a quarterly basis (Appendix A).
Kidney Disease Quality of Life Short-Form 36-items survey (KDQOL-SF36™)
KDQOL questionnaires (Appendix C) were administered to participants for both Henry
Ford and DaVita clinics. Although the KDQOL is designed to be a self-administered questionnaire,
given the low literacy rate of the enrolled subjects, it was determined that the questions be read
and responses recorded by a member from the PATCH clinical team. A stand-alone excel scoring
tool developed by the KDQOL Working Group was used to score all surveys [214].
Biochemical Outcome Measures
Lipid Profiles
Plasma TC and triglycerides (TAG) were determined by enzymatic assays (Pointe
Scientific Inc, Canton, MI, USA). High density lipoprotein cholesterol (HDL-C) was measured in
the supernatant after precipitation of apoB-containing lipoproteins by dextran sulfate and
magnesium ions (Pointe Scientific Inc, Canton, MI, USA). Low density lipoprotein cholesterol
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(LDL-C) was calculated using the Friedwald equation by difference (LDL-C = TC – HDL-C −
TAG/5). HDL and LDL subfractions from plasma were also measured via polyacrylamide gel
electrophoresis using the LipoprintTM System (Quantimetrix Corporation, Redondo Beach, CA,
USA). Using the manufacturer’s proprietary software, HDL and LDL subfractions were
quantitated after electrophoresis. Both HDL and LDL were then grouped into large buoyant,
intermediate lipoproteins, and small-dense lipoproteins. The LipoprintTM system is U.S. Food and
Drug Administration (FDA) certified for LDL measurements; however, values for HDL are for
research purposes only [82].
Inflammatory Markers
C-Reactive Protein (CRP), Interleukin 6 (IL-6), Interleukin 18 (IL-18), and Monocyte
Chemoattractant Protein-1 (MCP-1) samples were analyzed in duplicates in 384-well
AlphaPlatesTM (PerkinElmer®) (Figure 7) according to manufacture low volume protocol. 2 µL
of undiluted plasma was used for IL-6, IL-18 and MCP-1 assays, whereas 2 µL of plasma was
diluted 101 fold for CRP assays. Absorbance values obtained from the AlphaLISA assays were
analyzed using a nonlinear regression 4-parameter logistic equation (sigmoidal dose-response
curve with variable slope) and a 1/Y2 data weighting (Figure 8). The lowest detectable limit was
calculated by averaging background counts and adding that value to 3 times the standard deviation
value. All analyses for inflammatory markers were completed using GraphPad Prism software
(Version 8.3.0, GraphPad Software, LLC, San Diego, CA). IL-6 values lower than the detection
limit (1.3 pg/mL) were assigned a value of 0.01 pg/mL. Replicates with a coefficient of variation
greater than 10% were repeated.
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Anthropometrics
Body Mass and Stature
Height, pre-dialysis and post dialysis (dry) weights were obtained from the medical record.
Clinic staff measured height to the nearest 0.1cm (Tanita Wall Mounted Height Rod, Tanita, USA)
and body weight to the nearest 0.1kg after each HD session (Tronix Flush-Mounted In-Floor Scale,
Scale-Tronix, USA). BMI was calculated from the measurements of weight and height using
Quetelet’s Index [BMI (kg/m2) = weight (kg)/height (m2)][260].
Muscle Mass
Mid arm circumference (MAC) and triceps skin fold (TSF) thickness was measured
following International Society for Advancement of Kinanthropometry (ISAK) procedures [261]
by a single Level One trained ISAK Anthropometrist to eliminate inter-observer reliability. In
each dialysis clinic, subjects were transported either before or after their dialysis session into an
examination room to collect MAC and TSF measurements. Measurements were made on the side
of the body without vascular access using the following protocol:
(1) Locate the acromium and the olecranon process; mark these landmarks with an Expo
marker. (2) Measure the length between the acromium and the olecranon process and find the
midpoint; mark this midpoint with an Expo marker. (3) Measure the arm circumference at this
point to the nearest 0.1 cm with a ¼ inch Lufkin flexible steel tape measure (Apex Tool Group,
LLC, NC) which is placed gently but firmly around the arm to avoid compression. Record this
measurement (Figure 9) (4) Standing perpendicular to the subject, find the furthest point on the
triceps, and mark this site with an Expo marker. (5) Measure the TSF using Lange calipers
Cambridge Instrument, Cambridge, MA). Holding the skinfold 2.0 cm above the circumference
mark, place the tips of the caliper jaws over the complete skinfold. Ensure that the mark remains
centered between the tips and that the jaws sit perpendicular to the length of the skinfold. Continue
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to hold the skinfold in place and release the caliper handle to exert full tension on the skinfold.
Wait 3 seconds for the needle on the caliper dial to settle on an accurate measurement. (6) Repeat
MAC and TSF measurement; if the two measurements are more than 1 cm apart, repeat for a third
measurement (Figure 9)
MAC and TSF measurements were taken in duplicate using the non-fistula arm, with a
third measurement taken when disagreement between the first and second measurements was
greater than 10%. Mid arm muscle circumference (MAMC), as a marker of lean muscle mass, was
calculated using the formula: MAMC = MAC– (3.14 x TSF thickness) [154, 262].
Muscle Strength
Hand grip strength (HGS) measured by dynamometry is an indicator of muscle strength.
The mean of three grip strength trials using the non-fistula arm was measured with a dynamometer
using The American Society of Hand Therapists (ASHT) protocol. HGS was measured with
subjects seated with their shoulders adducted, their elbows flexed 90°, and their forearms in a
neutral position using a Jamar Plus dynamometer (Sammons Preston, Inc., Bolingbrook, IL) with
the handle at position 2 [263-265].
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Tables and Figures
Table 4: Inflammatory Effect Scores for Dietary Components Used for Calculation of DII
Food parameters
Inflammatory Effect Score*
Carbohydrates (g)
0.097
Cholesterol (mg)
0.11
Calories (kcal)
0.18
Fat (g)
0.298
Total Dietary Fiber (g)
-0.663
MUFA (g)
-0.009
Protein (g)
0.021
PUFA (g)
-0.337
Saturated Fat (g)
0.373
Trans Fatty Acid (g)
0.229
Vitamin B12 (mcg)
0.106
Vitamin B6 (mg)
-0.365
Beta-Carotene (mcg)
-0.584
Folic Acid (mcg)
-0.19
Vitamin B3 (mg)
-0.246
Vitamin B2 (mg)
-0.068
Vitamin B1 (mg)
-0.098
Vitamin A (RE)
-0.401
Vitamin C (mg)
-0.424
Vitamin D (mcg)
-0.446
Vitamin E (mg)
-0.419
Iron (mg)
0.032
Magnesium (mg)
-0.484
Selenium (mcg)
-0.191
Zinc (mg)
-0.313
Omega 3 Fatty Acid (g)
-0.436
Omega 6 Fatty Acid (g)
-0.159
Alcohol (g)
-0.278
Caffeine (mg)
-0.11
Adapted from Shivappa, et, al., 2014 [202].*A negative value indicates anti-inflammatory effect and a positive score
indicates pro-inflammatory effect; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid
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PATCH Malaysia
(NCT02913690)
Malaysia (n = 336)

PATCH USA
(NCT02358967)
Bangladesh (n = 102)

USA (n = 135)

India (n = 39)

African Americans (n = 128)

Screened out subjects for whom all six 24-hr dietary
recalls were deemed implausible (n = 27)

Plausible dietary reporters used for all analyses (n = 101)
Figure 5: Consort Diagram of PATCH Clinical Trial and Selection of Study Participants
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Figure 6: Flow Chart for Dietary Pattern Cluster Analysis Process
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Figure 7: Principles of the AlphaLISA® Assay
(Illustration by: Perkin Elmer®, Inc. 2017)
The AlphaLISA® assay uses a bead-based technology. The energy transferred from one bead to
the other produces a luminescent signal.
1) Analyte standard dilutions are prepared according to the manufacture’s protocol.
2) In white Optiplate-384 microplate, 2 µL of standard or plasma sample is added to each well
using an Eppendorf (K41494G) 8 channel automatic 0.5 – 10 µL pipette.
3) 8 µL of a 2.5X mixture of AlphaLISA Anti-Analyte Acceptor beads (10 μg/mL final) and
Biotinylated Antibody Anti-Analyte (1 nM final) are added to each well using an
Eppendorf Repeater® M4 pipettor fitted with a Combitip.
4) The plate is covered with a plate seal, spun briefly in a centrifuge, and placed on a shaker
plate to incubate for 60 minutes at 23°C.
5) 10 µL of 2X SA-Donor beads (40 μg/mL final) is added to each well.
6) The plate is resealed, spun briefly in a centrifuge, placed on a shaker plate for 3 minutes,
and incubated for 30 minutes at 23°C.
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7) The plate is read on an EnSpire plate reader.
After the biotinylated antibody and acceptor beads are added, the analyte is captured by the
antibody pair to create a sandwich assay. During the first incubation, the biotinylated antibody
binds to an epitope on the analyte of interest. The second antibody binds to a different epitope.
Once the streptavidin coated donor beads are added, the streptavidin-biotin interaction pulls the
complex together, bringing the two beads into close proximity. Donor beads, which contain a
photosensitizer (phthalocyanine), converts oxygen to an excited and reactive form of O2 once
illuminated at 680 nm, causing a release of singlet oxygen molecules. The singlet oxygen initiates
a cascade of reactions inside the acceptor bead, resulting in a transfer of energy from the singlet
oxygen to thioxene derivatives within the acceptor bead, producing light production at 615 nm.
The emission wavelength is shorter than the excitation, resulting in less background interference.
The higher the concentration of the analyte of interest, the more bead complexes are brought
together, which results in a signal intensity proportional to the concentration of the analyte. In the
absence of an acceptor bead, singlet oxygen falls to ground state and no signal is produced.
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Position for upper arm length and
Triceps skin fold measurement
midpoint
Figure 9: MAC and TSF Measurement (source: GWAS Samoa 2010 – Fieldwork Manual [266])
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CHAPTER 3: RESULTS – SPECIFIC AIM ONE: TO CHARACTERIZE THE
NUTRITION AND HEALTH STATUS IN A COHORT OF AFRICAN AMERICAN
MAINTENANCE HEMODIALYSIS PATIENTS
SUB AIM 1A: To Characterize the Overall Study Population
General Characteristics
The general characteristics of the study participants, displayed in Table 5, did not vary
significantly between gender. A total of 101 patients were included in this study, of whom 59%
were male; the mean age was 60 years and the average time spent on dialysis was 63 months. One
third of the cohort were tobacco users and two-thirds had DM. Women had significantly higher
BMI levels compared to men and half of all female subjects had a BMI exceeding 30 kg/m2
(overweight). The mean Kt/V for the entire cohort was 1.54 ± 0.24. Mean systolic blood pressure
did not differ between gender, while mean diastolic readings were significantly lower among
females. Approximately half of the study participants were prescribed a renal specific vitamin and
one out of five, an antidepressant medication.
Biochemical Characteristics
Biochemical data collected from the HD clinics are shown in Table 6. Measures to assess
anemia, hemoglobin, iron, ferritin and transferrin saturation, did not differ significantly between
gender. Mean serum ferritin levels for all patients were 757 ± 355 ng/mL; mean hemoglobin levels
were 10.8 ± 2.3 g/dL. Serum creatinine levels were significantly higher for males as compared to
females, most likely reflective of larger muscle mass. Mean serum potassium was 4.6 ± 0.6 mEq/L,
mean serum phosphorus was 5.1 ± 1.2 mg/dL, and mean serum albumin was 3.8 ± 0.3 g/dL; all
three of these measures did not differ between genders.
Nutritional Analysis
Macronutrient and micronutrient intakes are presented in Table 7. Although caloric intake
and associated micronutrients were significantly higher among males, the macronutrient

61
distribution did not differ between genders. Approximately 17% of consumed calories were from
protein, 40% from fat (12% from saturated fat), and 43% from carbohydrates. For both genders,
daily mean intakes for added sugars was 88 grams/day, which is the equivalent to approximately
one half cup of sugar (350 calories), which exceeds the American Heart Association’s guideline
of no more than 36 grams daily. Per the RDA’s dietary fiber recommendations for males and
females (30 and 21 grams/day, respectively), males met only 43% of the recommended amount
and females, 57% [267]. Intakes for sodium, phosphorus, and potassium exceeded recommended
guidelines by 76%, 22%, and 82%, respectively, while almost all patients fell below recommended
intakes for several micronutrients, including vitamins C, E, K, zinc, and magnesium (Table 8).
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Table 5: Baseline Clinical Characteristics of the Study Population
All
Males
Females
(n = 101)
(n = 60)
(n = 41)
Age, y
60 ± 13
Dry weight (kg)
84 ± 19
Height (cm)
172 ± 11
2
BMI, kg/m
28.4 ± 6.6
Obese (BMI > 30), %
36 (36)
Vintage (months)
63 ± 63
IDWG (kg)
2.7 ± 1.4
UFR (mL/kg/hr)
6.6 ± 4.1
DM, n (%)
58 (57)
Tobacco Use, n (%)
29 (29)
Vascular Access
Arteriovenous fistula, n (%)
59 (58)
Arteriovenous graft, n (%)
27 (27)
Catheter, n (%)
15 (15)
Blood Pressure, mmHg (post-sitting)
1
Systolic
140 ± 23
1
Diastolic
79 ± 17
Kt/V
1.54 ± 0.24
Antidepressant use, %
17 (17)
Renal vitamin* use, %
56 (55)

p value
between
groups
0.419
< 0.001
0.367
0.016
0.036
0.543
0.129
0.172
0.852
0.058

59 ± 14
86 ± 22
178 ± 8
27.1 ± 6.3
15 (25)
66 ± 67
2.8 ± 1.5
7.0 ± 4.4
34 (57)
13 (22)

61 ± 12
82 ± 18
165 ± 7
30.3 ± 6.6
21 (51)
59 ± 56
2.4 ± 1.3
5.9 ± 3.6
24 (59)
16 (39)

33 (55)
18 (30)
9 (15)

26 (63)
9 (22)
6 (15)

0.642

138 ± 23
82 ± 20
1.53 ± 0.21
8 (13)
34 (57)

144 ± 23
74 ± 9
1.56 ± 0.27
9 (22)
22 (54)

0.240
0.023
0.559
0.256
0.765

Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test. BMI: Body
Mass Index; IDWG: Interdialytic Weight Gain; UFR: Ultrafiltration Rate; DM, diabetes mellitus; Kt/V is a number
used to quantify hemodialysis (K, dialyzer clearance of urea; t, dialysis time; V, volume of distribution of urea,
approximately equal to patient’s total body water) *Renal vitamins included Nephrocaps, Renal Caps, and Nephrovite
brands. 1BP (n = 88)
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Table 6: Baseline Clinic Reported Biochemical Characteristics of the Study Population
All
Males
Females
p value
(n = 97)
(n = 57)
(n = 40)
between
groups
Serum Potassium (mEq/L)
4.6 ± 0.6
4.6 ± 0.6
4.6 ± 0.6
0.725
Serum Phosphorus (mg/dL)
5.1 ± 1.2
5.3 ± 1.3
4.9 ± 1.0
0.102
Serum Albumin (g/dL)
3.8 ± 0.3
3.8 ± 0.4
3.8 ± 0.3
0.757
Corrected Calcium (mg/dL)
9.3 ± 0.7
9.3 ± 0.8
9.3 ± 0.5
0.662
Serum Creatinine (mg/dL)
9.3 ± 2.7
9.9 ± 2.8
8.4 ± 2.4
0.008
Serum Hemoglobin (g/dL)
10.8 ± 2.3
10.7 ± 1.4
11.0 ± 3.2
0.650
Serum Iron (μg/dL)
74 ± 39
65 ± 23
85 ± 53
0.060
Serum Ferritin (ng/mL)
757 ± 355
718 ± 344
812 ± 369
0.212
TSAT (%)
30 (11)
31 (9)
31 (13)
0.572
Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test. TSAT:
Transferrin Saturation
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Table 7: Nutrient Intake of the Study Population

Calories (kcals)
Protein (g)
% kcals from protein
Fat (g)
% kcals from fat
Saturated fat (g)
% kcals from SFA
Cholesterol (mg)
Carbohydrate (g)
% kcals from carbohydrate
Fiber (g)
Sugar (g)
Phosphorus (mg)
Iron (mg)
Magnesium (mg)
Sodium (mg)
Potassium (mg)
Zinc (mg)
Vitamin C (mg)
Calcium (mg)
Chromium (mcg)
Selenium (mg)
Folate (mcg)
Cholesterol (mg)
Vitamin A (IU)
Vitamin D (IU)
Vitamin E (mg)
Vitamin K (mcg)

All
(n = 101)

Males
(n = 60)

Females
(n = 41)

2033 ± 417
86 ± 26
17 ± 4
91 ± 25
40 ± 7
28 ± 9
12 ± 3
417 ± 182
219 ± 65
43 ± 8
12 ± 4
88 ± 45
837 ± 303
11 ± 4
149 ± 64
3004 ± 960
1503 ± 583
8.5 ± 4.1
57 ± 46
436 ± 154
4.4 ± 6.9
89 ± 38
224 ± 108
417 ± 182
3563 ± 3290
90 ± 74
4.2 ± 3.1
56 ± 80

2183 ± 417
94 ± 28
17 ± 5
96 ± 23
40 ± 7
30 ± 9
12 ± 3
431 ± 191
236 ± 72
43 ± 8
13 ± 4
93 ± 49
924 ± 325
12 ± 4
168 ± 69
3190 ± 1021
1653 ± 599
9.4 ± 4.1
63 ± 47
165 ± 21
5.0 ± 7.8
94 ± 42
239 ± 120
431 ± 191
3385 ± 3155
94 ± 87
4.6 ± 3.5
58 ± 81

1815 ± 311
75 ±18
17 ± 4
83 ± 24
41 ± 7
26 ± 8
13 ± 3
396 ± 169
193 ± 44
43 ± 8
12 ± 5
80 ± 38
709 ± 215
10 ± 5
120 ± 43
2731 ± 798
1283 ± 487
7.1 ± 3.8
49 ± 43
125 ± 20
3.4 ± 5.0
81 ± 29
204 ± 84
396 ± 169
3823 ± 3502
85 ± 49
3.7 ± 2.4
53 ± 81

p value
between
groups
< 0.001
< 0.001
0.376
0.007
0.463
0.008
0.722
0.331
< 0.001
0.881
0.122
0.122
< 0.001
0.076
< 0.001
0.013
0.001
0.005
0.117
0.011
0.244
0.074
0.090
0.331
0.522
0.528
0.148
0.791

Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test. kcals:
kilocalories
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Table 8: Percentage of Patients Outside the Recommended Intake Limits of Micronutrients
All
Nutrient
Patients (%) outside
(n = 101)
recommendations for the recommended
HD [154]
intake limits
Sodium, mg/d
2858 [2345 – 3581]
750 – 2000
90
Phosphorus, mg/d
791 [621 – 988]
≤ 800 – 1000
22
Potassium, mg/d
1457 [1096 – 1770]
800 – 1000
82
Calcium, mg/d
421 [320 – 497]
≤ 1000
none
Magnesium, mg/d
135 [109 – 175]
200 – 300
97
Selenium, mg/d
87 [62 – 105]
55*
18
Zinc, mg/d
7.6 [5.9 – 10.6]
15
90
Vitamin A, IU/d
2149 [1347 – 4862]
700-900
6
Vitamin C, mg/d
48 [24 – 86]
75 – 90
71
Vitamin E, mg/d
3.3 [2.3 – 5.4]
15
97
Vitamin K, mcg/d
30 [13 – 60]
90 – 120
87
Values are expressed as median [interquartile range (IQR)]. No guidelines specific to HD population available;
Recommended Dietary Allowance(RDA)/Dietary Guidelines for Americans DGA used[267, 268]
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SUB AIM 1B: To Assess Protein Energy Wasting (PEW), Dyslipidemia, and Inflammation
in the Study Population
Protein Energy Wasting (PEW)
Patients were identified as having PEW if three of the four criteria were met: (1) albumin
< 3.8mg/dL, (2) BMI < 23 kg/m2, (3) reduced mid-arm muscle circumference area (reduction >
10% in relation to 50th percentile of reference population), and (4) either DEI < 25 kcals/kg or
DPI < 0.8 grams/kg recorded for one of the 24-hr dietary recalls. Figure 10 shows a frequency
distribution of PEW prevalence for each of four criteria. 60% of patients had a low DEI or DPI,
41% had a low albumin level, 23% had a low BMI, and 15% had a low MAMC. Only five patients
(5%) were identified as having three of the four diagnostic criteria for PEW.
Using the EWGSOP2 sarcopenia cut-off points for low grip strength (27 kg and 16 kg for
men and women, respectively), 27% of males and 19% of females met the criteria for probable
sarcopenia (Table 9). Further analyses were conducted to examine the differences in biomarkers,
macronutrient, and micronutrient intakes as well as self-reported outcome measures. Patients
meeting the criteria for probable sarcopenia tended to be older (64 ± 13 vs. 59 ± 12 years) and
have a longer dialysis vintage (98 ± 105 vs 60 ± 52 months); however, these differences were not
significant. No significant differences in inflammatory markers were found between sarcopenic
and non-sarcopenic patients, with the exception of CRP (6.9 ± 2.1 vs 4.3 ± 2.8 mg/L, p = 0.003),
which was significantly higher for those patients with probable sarcopenia.
Dyslipidemia and Inflammation
The biochemical characteristics of the study participants are presented in Table 10. One
subject with hypertriglyceridemia (plasma TAG 943 mg/dL) was excluded from all subsequent
analyses. In comparison to males, female patients presented with significantly higher TC, HDL-
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C, and large and intermediate HDL, and large LDL subfractions. Males were about twice as likely
(RR = 1.95) to have an atherogenic Pattern B phenotype than females.
Using a threshold of non-HDL cholesterol > 100 mg/dL to identify patients with
dyslipidemia [269], 44% of the cohort were classified as dyslipidemic. For the entire cohort, both
large and intermediate HDL and LDL subfractions were more prevalent in contrast to small HDL
and LDL subfractions.
Using a TG/HDL-C ratio of 3.8, as derived from the Adult Treatment Panel target
recommendations of TG > 150 mg/dl and HDL-C < 40 mg/dl, only 15% of patients were
categorized as having a TG/HDL ratio of > 3.8 [270]. Results from a t-test comparing
inflammatory markers for those patients with a TG/HDL-C ratio > 3.8 vs < 3.8, respectively
showed the following difference in means: MCP-1 (123 ± 85 vs. 148 ± 117, NS), IL-6 (1.5 ± 3.1
vs. 14.0 ± 50.6, p = 0.028), and IL-18 (219 ± 130 vs. 277 ± 158, NS), thus patients with a TG/HDLC ratio > 3.8 tended towards lower levels of inflammatory markers.
Correlations between malnutrition and inflammation indicators are presented on Table 11.
BMI was positively correlated with both TSF, r(45) = 0.78, p < 0.001 and MAMC, r(45) = 0.76,
p < 0.001. There was a significant, moderately positive correlation between HGS and serum
creatinine, r(45) = 0.43, p = 0.003. MAMC and HGS were positively correlated, but the
relationship was not significant. The only inflammatory marker found to be associated with
anthropometric measures was CRP, which had a weak, positive association with BMI, r(97) =
0.25, p = 0.013.
Significant associations were found among the measured cytokines illustrated on Figure
11. IL-18 was moderately positively associated with its downstream products, MCP-1, r(94) =
0.46, p < 0.001 and IL-6, r(97) = 0.48, p < 0.001. However, no significant associations were found
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between the cytokines and CRP. Additionally, a negative weak association was found between
CRP and albumin, r(93) = -0.28, p = 0.005.
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Table 9: Baseline Anthropometric Measures of the Study Population
All (n = 47)
Males
Females
(n = 26)
(n = 21)
Hand Grip Strength (kg) 25.8 ± 10.0
30.8 ± 10.7
19.7 ± 3.6
TSF (mm)
16.6 ± 9.9
15.1 ± 10.2
18.5 ± 9.3
MAMC (cm)
27.5 ± 4.2
27.3 ± 3.5
27.8 ± 4.9
Low Grip Strength
11 (23)
7 (27)
4 (19)

p value between
groups
< 0.001
0.245
0.718
0.526

Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test; BMI:
Body Mass Index; TSF: triceps skin fold; MAMC: mid-arm muscle circumference.
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Table 10: Baseline Lipid and Inflammatory Characteristics of the Study Population
1
All
Males
Females
p value
(n = 100)
(n = 59)
(n = 41)
between
groups
CRP (mg/L)
6.1 ± 4.0
6.4 ± 4.6
5.6 ± 2.9
0.273
IL-6 (pg/mL)
12.1 ± 46.7
16.9 ± 59.5
5.3 ± 13.1
0.157
IL-18 (pg/mL)
268 ± 155
292 ± 179
230 ± 99
0.003
MCP-1 (pg/mL)
144 ± 112
168 ± 137
109 ± 45
0.003
Total Cholesterol (mg/dL)
151 ± 44
141 ± 41
165 ± 46
0.007
Triglycerides (mg/dL)
96 ± 52
91 ± 50
104 ± 56
0.237
LDL-C (mg/dL)
80 ± 40
75 ± 35
86 ± 47
0.204
HDL-C (mg/dL)
52 ± 19
47 ± 17
58 ± 21
0.007
non-HDL-C > 100 mg/dl (n, %)
44 (44)
22 (37)
22 (54)
0.105
TG/HDL-C > 3.8
15 (15)
7 (12)
8 (20)
0.292
Large HDL (mg/dL)
22.8 ±16.2
19.5 ± 13.1
27.5 ± 19.1
0.023
Intermediate HDL (mg/dL)
22.8 ± 5.8
21.6 ± 5.6
24.6 ± 5.8
0.012
Small HDL (mg/dL)
6.1 ± 3.3
6.0 ±3.1
6.2 ± 3.5
0.764
Large LDL(mg/dL)
21.9 ± 9.7
19.5 ± 8.6
25.5 ± 10.3 0.003
Intermediate LDL (mg/dL)
12.7 ± 8.1
11.8 ± 6.9
14.0 ± 9.6
0.230
Small LDL (mg/dL)
3.9 ± 5.5
4.3 ± 5.0
3.5 ± 6.2
0.506
Mean LDL Size (Å)
269 ± 4
269 ± 5
270 ± 4
0.046
LDL Pattern A, n (%)
62 (62)
31 (53)
31 (80)
0.024
LDL Pattern B, n (%)
16 (16)
12 (20)
4 (10)
Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test. 1One subject
with hypertriglyceridemia (plasma TAG 943 mg/dL) excluded from table. CRP: C-reactive protein; IL-6: Interleukin
6; IL-18: Interleukin 18; MCP-1: Monocyte Chemoattractant Protein-1; HDL: high density lipoprotein cholesterol;
LDL: low density lipoprotein cholesterol; Å: angstrom.
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Table 11: Correlation Matrix for Anthropometric and Inflammation Indicators
Variable
MCP-1
IL-18
IL-6
Alb
Creat
TSF
MAMC
HGS
BMI
DII

CRP

MCP-1

IL-18

IL-6

Alb

Creat

TSF

MAMC

HGS

BMI

0.12
-0.06
0.46***
0.05
0.48***
0.50***
**
-0.28
-0.08
0.04
0.10
-0.10
0.19
0.26**
0.28** -0.20* 0.24
-0.06
0.07
0.13
-0.20 0.06
0.09
0.00
-0.19
0.08
-0.25 0.21
0.45***
***
-0.26
0.28
0.06
-0.07
-0.14 0.43
0.56
0.27
0.25**
-0.18
-0.10
-0.06
-0.01 -0.05
0.78***
0.76***
0.03
-0.12
-0.04
-0.06
-0.19
0.20
-0.09
0.01
-0.07
-0.12 -0.11
*
P < 0.05; **P < 0.01; ***P < 0.001
CRP: C-reactive protein; MCP-1: Monocyte Chemoattractant Protein-1; IL-18: Interleukin 18; IL-6: Interleukin 6;
Alb: albumin; Creat: creatinine; TSF: Triceps Skin Fold; MAMC: Mid arm muscle circumference; HGS: Hand Grip
Strength; BMI: Body Mass Index; DII: Dietary inflammatory index
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Figure 10: Frequency Distribution of PEW Prevalence for Each of Four Criteria
ALB: albumin (n= 96); BMI: Body Mass Index (n = 101); MAMC: mid arm muscle circumference (n = 47); DEI:
dietary energy intake and DPI: dietary protein intake (DPI) (n = 101)
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Figure 11: Plasma Cytokine Correlations for IL-18 and MCP-1, MCP-1 and IL-6, and IL-6 and
CRP
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SUB AIM 1C: To Evaluate Phosphorus to Protein Ratio and Dietary Inflammatory Index
From the Derived Nutrition Information
Associations with Egg Intake
For those participants who reported consuming egg, bivariate (Pearson) correlations were
conducted to examine the relationship between percent of total energy intake (% TE) contribution
from egg and outcome measures. Higher % TE from egg was negatively associated with HGS,
r(32) = -0.37, p = 0.034 and positively associated with PTH, r(84) = 0.33, p = 0.002.
A multivariate analysis (Table 12 and Table 13) was conducted to examine the differences
in serum chemistry and BMI between those participants who reported any egg consumption against
those who did not report egg consumption. To reduce confounding, a separate analysis was
conducted for each gender and results were adjusted for age. No differences were observed for
BMI, serum lipids, phosphorus, albumin, and PTH for both genders, with the exception of TC in
men; egg consumers had a significantly lower TC (132 ± 37 mg/dL) as compared to nonconsumers (160 ± 43 mg/dL).
The mean DII score was 3.1 ± 1.1 (min, -0.54; max, 5.83). A gender stratified analysis was
conducted to examine differences in inflammatory markers, serum albumin and creatinine, and
dietary intake according to DII (Table 14). Scores ranging from -0.54 to 3.26 were classified as
“lower DII scores” while scores ranging from 3.27 to 5.83 were classified as “higher DII scores.”
No differences were found between those with lower and higher DII scores for inflammatory
markers, serum albumin and serum creatinine for both genders. Significant differences in PUFA
intake was found between lower and higher DII score groups. For both males and females,
consuming fewer calories from PUFA was significantly associated with higher DII scores. Males
in the higher DII group consumed significantly less α-linolenic (ALA) and linoleic acid (LA) than
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those in the lower DII group. Lower intakes of both ALA and LA were also found for females who
consumed more inflammatory diets.
It is worth noting that both males and females in the entire cohort fell short of the
Recommended Dietary Allowance (RDA) for α-linolenic acid, which is 1.6 and 1.1 grams/day,
respectively, for males and females ages 51 to 70. Only subjects who fell in the lower DII score
groups met the RDA for linoleic acid (14 and 11 grams/day, respectively for males and females
for ages 51 to 70) [267].
Phosphorus to Protein (P/Pro) Ratio
Comparisons between those subjects consuming “favorable” p/pro ratio of less than 10
mg/g and those consuming “unfavorable” ratios of greater than 10 mg/g were compared (Table
14). A cutoff value of 10 mg/g as the upper end of favorable was used based on current
recommendations per Noori, et al. [156]. No significant differences were found in serum
chemistry, namely serum phosphorus and PTH. No differences were found in serum lipids and
inflammatory markers. Significantly higher intakes of percent calories from MUFAs and PUFAs
were observed in the “unfavorable” p/pro group. Gram intake of eggs was higher in the unfavorable
p/pro group, but this difference was not significant.
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Table 12: Multivariate Analysis of Egg Non-Consumers Versus Consumers for Men
Did not consume Consumed eggs
95 % CI
eggs
(n = 38)
Lower
Upper
(n = 17)
limit
limit
2
BMI, kg/m
26.1 ± 4.6
27.4 ± 6.8
-4.96
2.42
Total Cholesterol (mg/dL)
160 ± 43
132 ± 37
3.35
49.16
Triglycerides (mg/dL)
109 ± 61
84 ± 43
-6.04
51.55
LDL-C (mg/dL)
89 ± 37
70 ± 34
-1.50
40.12
HDL-C (mg/dL)
49 ± 24
46 ± 13
-7.31
12.09
Serum Phosphorus (mg/dL)
5.3 ± 1.2
5.3 ± 1.4
-0.88
0.64
Serum Albumin (g/dL)
3.9 ± 0.4
3.8 ± 0.3
-0.19
0.22
PTH
466 ± 255
700 ± 715
-617.76
109.96
Adjusted for age; One subject with hypertriglyceridemia (plasma TAG 943 mg/dL) excluded from table.

p value
0.493
0.026
0.119
0.068
0.623
0.749
0.901
0.167
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Table 13: Multivariate Analysis of Egg Non-Consumers Versus Consumers for Women
Did not consume Consumed eggs
95 % CI
eggs
(n = 34)
Lower
Upper
(n = 6)
limit
limit
2
BMI, kg/m
34.3 ± 5.2
29.6 ± 6.7
-1.94
11.60
Total Cholesterol (mg/dL)
146 ± 42
166 ± 44
-66.97
24.68
Triglycerides (mg/dL)
103 ± 60
103 ± 56
-57.25
61.03
LDL-C (mg/dL)
75 ± 44
85 ± 45
-60.75
32.28
HDL-C (mg/dL)
51 ± 20
60 ± 21
-29.16
14.58
Serum Phosphorus (mg/dL)
5.4 ± 1.3
4.8 ± 1.0
-0.64
1.45
Serum Albumin (g/dL)
3.7 ± 0.1
3.8 ± 0.3
-0.53
0.06
PTH
460 ± 429
705 ± 612
-809.04
419.37
Adjusted for age

p value
0.157
0.356
0.949
0.539
0.504
0.438
0.108
0.524
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Table 14: Characteristics of the Patients According to Lower and Higher Dietary Inflammatory
Intake Scores (DII)
Males
Females
Characteristics
Lower DII Higher DII
Lower DII Higher DII
scores
scores
p value
scores
scores
p value
(n = 34)
(n = 26)
(n = 16)
(n = 25)
DII
2.2 ± 0.9
4.0 ± 0.6 < 0.001 2.5 ± 0.5
3.9 ± 0.4 < 0.001
CRP (mg/L)
6.8 ± 5.2
5.9 ± 3.6
0.471
4.7 ± 2.5
6.2 ± 3.1
0.106
IL-6 (pg/mL)
20.6 ± 69.7 11.5 ± 42.6 0.541 6.6 ± 19.3
4.4 ± 6.8
0.671
IL-18 (pg/mL)
293 ± 185
288 ± 172
0.925
218 ± 90
239 ± 106
0.520
MCP-1 (pg/mL)
156 ± 64
181 ± 193
0.538
114 ± 52
106 ± 40
0.597
Serum Alb (g/dL)
3.8 ± 0.4
3.9 ± 0.3
0.591
3.7 ± 0.4
3.9 ± 0.2
0.177
Serum Cr (mg/dL)
9.9 ± 3.0
9.6 ± 2.7
0.691
7.9 ± 1.8
8.7 ± 2.7
0.265
% kcal from fat
39 ± 7
40 ± 6
0.595
38 ± 8
42 ± 6
0.050
% kcal from SFA
12 ± 3
13 ± 2
0.027
12 ± 3
13 ± 2
0.492
% kcal from PUFA
7±3
5±3
0.002
7±3
5±2
0.033
% kcal from MUFA
13 ± 4
9±5
0.005
11 ± 4
11 ± 4
0.539
ALA
1.0 ± 0.5
0.7 ± 0.4
0.021
0.8 ± 0.4
0.6 ± 0.2
0.072
LA
13.8 ± 9.3
8.4 ± 4.7
0.005 11.5 ± 7.5
7.5 ± 3.0
0.056
DII: Dietary inflammatory index; Lower scores: -0.54 to 3.26 and higher scores: 3.27 to 5.83; CRP: C-reactive protein;
IL-6: Interleukin 6; IL-18: Interleukin 18; MCP-1: Monocyte Chemoattractant Protein-1; Alb: albumin; Cr: creatinine;
kcal: kilocalories; SFA: Saturated fatty acids: polyunsaturated fatty acids; MUFA: monounsaturated fatty acids; ALA:
Alpha-linolenic acid; LA: Linoleic acid
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Table 15: Differences Between “Favorable” and “Unfavorable” P/Pro Ratios
P/Pro < 10 mg/g
P/Pro > 10 mg/g
p value between
(n=55)
(n=46)
groups
Serum Chemistry
Potassium (mEq/L)
4.6 ± 0.7
4.7 ± 0.5
0.670
Phosphorus (mg/dL)
5.0 ± 1.3
5.2 ± 1.1
0.649
Albumin (g/dL)
3.8 ± 0.4
3.8 ± 0.3
0.688
Creatinine (mg/dL)
9.3 ± 3.0
9.2 ± 2.5
0.853
PTH
580 ± 493
706 ± 105
0.316
2
BMI (kg/m )
29.3 ± 7.1
27.3 ± 5.8
0.125
IDWG (kg)
2.7 ± 1.3
2.7 ± 1.6
0.921
UFR (mL/kg/hr)
7.2 ± 4.3
5.8 ± 3.8
0.095
Dietary Nutrients
p/pro ratio (mg/g)
8.1 ± 1.7
12.0 ± 2.2
< 0.001
grams pro/kg BW
26 ± 6
25 ± 5
0.525
% kcals from carbohydrate
43 ± 7
43 ± 9
0.639
% kcals from protein
18 ± 4
17 ± 4
0.424
% kcals from fat
40 ± 6
40 ± 7
0.696
% kcals from carbohydrate
43 ± 7
43 ± 9
0.639
% kcals from SFA
13 ± 3
12 ± 3
0.746
% kcals from MUFA
10 ± 3
13 ± 4
< 0.001
% kcals from PUFA
5±2
7±3
< 0.001
Egg intake (g)
44 ± 42
62 ± 49
0.059
Values are expressed as means ± SDs. Statistics: 2-sample t test. “favorable” p/pro group: < 10 mg/g; “unfavorable”
p/pro group: > 10 mg/g PTH: parathyroid hormone; BMI: body mass index; IDWG: interdialytic weight gain; UFR:
ultrafiltration rate; BW: body weight SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA:
polyunsaturated fatty acids.
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CHAPTER 4: RESULTS – SPECIFIC AIM TWO: TO EVALUATE THE ASSOCIATION
OF CLUSTER ANALYSIS DERIVED DIETARY PATTERNS WITH HEALTH
OUTCOMES IN A COHORT OF AFRICAN AMERICAN MAINTENANCE
HEMODIALYSIS PATIENTS
Clusters Identified for Dietary Patterns
Two major dietary patterns were identified: (Cluster 1) a high “sugar sweetened beverage”
pattern (hiSSB) and (Cluster 2) a low “sugar sweetened beverage” pattern (loSSB). As illustrated
in Table 16, the hiSSB dietary pattern was characterized by higher energy contributions from
calorically sweetened soft and juice drinks (p < 0.001) and poultry (p < 0.05), whereas the greatest
energy contributors to the loSSB group was unprocessed red meat (p < 0.05), fish and shellfish, (p
< 0.05), and custard style desserts such as puddings, ice cream, and cheesecake (p < 0.05). A total
of 54 patients were classified in the loSSB pattern and 47 patients in the hiSSB pattern.
Characteristics of Patients According to Dietary Cluster
Baseline characteristics of the subjects were compared according to diet clusters. One
subject with hypertriglyceridemia (plasma TAG 943 mg/dL) was considered an influential outlier
and was therefore excluded the analyses to minimize statistical bias. Clinical parameters did not
differ significantly between the two diet clusters. Compared to patients in the loSSB group, those
in the hiSSB group had a significantly higher BMI and were more likely prescribed an
antidepressant. Both total HDL cholesterol as well as large HDL subfractions were significantly
lower in the hiSSB group as compared to the loSSB group. Patients in the hiSSB group were 2.4
times more likely to present a pattern B phenotype, which is distinguished by smaller and denser
LDL subfractions. Although the association was not significant, the hiSSB dietary pattern tended
towards higher inflammatory markers for CRP, IL-18, and MCP-1 (Table 17).
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Nutrient Intake According to Dietary Cluster
The nutrient intake of the subjects according to their diet cluster is illustrated in Table 18.
The two dietary clusters differed significantly in macronutrient distribution, with a larger
proportion of energy intake from fat and protein in the loSSB group and from carbohydrate in the
hiSSB group. Macronutrient intakes for cholesterol were significantly higher in the loSSB group
and intakes for total energy and sugar were significantly higher in the hiSSB group. Micronutrient
intakes differed significantly between groups for chromium (Cr), selenium (Se), vitamin C, and
zinc (Zn). Intakes for Cr, Se and Zn were lower in the hiSSB group as compared to the loSSB
group.
Based on the RDA, both clusters exceeded the Acceptable Macronutrient Distribution
Ranges (AMDR) for fat [267] and the Dietary Guidelines for Americans (DGA) recommendations
for both sodium and sugars [268]. Intakes for fiber, magnesium (Mg), Zn, vitamins C and E, Cr,
and folic acid fell below RDA guidelines for both groups [267]. USDA My Plate recommendations
fell below recommended minimum serving amounts for grains, vegetables, fruits, and dairy. The
hiSSB group exceeded the minimum recommended servings for protein by 132% and the loSSB
cluster, by 162% [271].
KDQOL Among MHD Patients According to Diet Clusters Among MHD Patients
Figure 12 illustrates the difference in KDQOL scores according to diet clusters. Compared
to those in the loSSB dietary pattern cluster, patients in the hiSSB cluster scored lower baseline
values on all five KDQOL domains and significantly lower on the S12 mental composite domain
(p < 0.026). To compare KDQOL scores across each domain for additional variables, a univariate
analysis was conducted (Table 19). The burden composite score was positively associated with

82
vintage; symptoms and effects scores were positively associated with age, and the physical
component summary score was negatively associated with vintage.
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Table 16: Percentage of Energy Contribution of Food Groups
Pattern 1
Pattern 2
(hiSSB)
(loSSB)
Food Groups
Mean (SD) %TE food
Sugar sweetened beverages
27.97 ± 9.27
9.45 ± 5.65
Unprocessed red meat
0.95 ± 1.49
2.17 ± 3.49
Poultry
4.67 ± 5.99
2.51 ± 2.47
Fish and shellfish
0.49 ± 0.93
1.42 ± 2.87
Puddings, ice cream, cheesecake
0.24 ± 0.78
0.76 ± 1.70
Processed and cured meats (bacon, sausage, hot
2.67 ± 2.47
3.62 ± 3.39
dogs)
Dairy, low-fat and 2%
1.75 ± 4.61
0.59 ± 2.30
Egg and egg dishes
2.43 ± 2.60
3.29 ± 3.08
Vegetables, canned, fresh and frozen
3.25 ± 4.20
4.45 ± 4.11
Fast foods, frozen and convenience entrees
4.46 ± 6.67
2.92 ± 4.87
Pizza, pasta and lasagna
2.77 ± 4.95
4.25 ± 6.58
Butter, margarine, animal fats
0.25 ± 0.41
0.41± 0.95
Potatoes, mashed and salad
0.87 ± 2.16
1.39 ± 2.55
Beans and legumes
0.43 ± 1.25
0.75 ± 1.92
Potatoes, fried and hash browns
1.39 ± 2.26
0.96 ± 2.18
Fruit, canned, fresh and dried
2.02 ± 4.61
1.28 ± 2.53
Oils (vegetable, olive, canola)
0.03 ± 0.09
0.05 ± 0.20
Crackers, chips and popcorn
2.12 ± 4.80
1.60 ± 2.57
Candy
0.47 ± 1.11
0.34 ± 1.01
Sauce and condiments, savory
0.83 ± 1.50
0.69 ± 0.92
Nuts and seeds and nut butters
0.24 ± 0.84
0.17 ± 0.86
Dairy, full-fat and creamer
1.00 ± 3.00
0.75 ± 3.18
Cakes, cookies, pie, donuts, and rich dough
1.71 ± 2.34
1.78 ± 2.70
Grains
6.38 ± 8.63
6.62 ± 8.26
Pork
0.71 ± 2.22
0.76 ± 1.65
Sauces and condiments, sweet
0.40 ± 0.62
0.39 ± 0.68

p value
< 0.001
0.022
0.024
0.028
0.049
0.106
0.122
0.132
0.151
0.194
0.200
0.256
0.270
0.315
0.330
0.335
0.398
0.509
0.542
0.597
0.665
0.691
0.885
0.888
0.889
0.945

Adapted from Tallman, et al. Nutrients, 2020 12(3), 797.
Values are mean ±SD; n=47 for hiSSB and 54 for the loSSB group. %TE food: the percentage total energy
contribution from food.
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Table 17: Patient Characteristics at Baseline According to Diet Cluster
All
hiSSB
(n = 100)
(n = 47)
Age, y
Males, n (%)
BMI, kg/m2
Vintage (months)
Obese (BMI > 30), %
DM, n (%)
Tobacco Use, n (%)
2
Kt/V
Antidepressant use, %
Renal vitamin* use, %
Serum Potassium (mEq/L)
Serum Phosphorus (mg/dL)
3
Serum Albumin (g/dL)
4
CRP (mg/L)
4
IL-6 (pg/mL)
5
IL-18 (pg/mL)
4
MCP-1 (pg/mL)
Total Cholesterol (mg/dL)
Triglycerides (mg/dL)
LDL-C (mg/dL)
HDL-C (mg/dL)
Large HDL (mg/dL)
Intermediate HDL (mg/dL)
Small HDL (mg/dL)
6
Large LDL(mg/dL)
6
Intermediate LDL (mg/dL)
6
Small LDL (mg/dL)
6
Mean LDL Size (Å)
LDL Pattern A, n (%)
LDL Pattern B, n (%)

60 [53 - 68]
59 (59)
27.4 [23.3 - 31.4]
45 [19 - 88]
36 (36)
57 (57)
29 (29)
1.5 [1.4 - 1.6]
17 (17)
56 (56)
4.6 [4.1 - 5.1]
5.0 [4.3 - 5.8]
3.8 [3.6 - 4.0]
6.1 [3.1 - 8.4]
1.7 [0.01 - 5.3]
238 [172 - 320]
113 [89 - 160]
148 [113 - 188]
81 [53 - 125]
76 [46 - 104]
47 [39 - 62]
17.0 [11.0 – 31.8]
23.0 [18.3 – 26.0]
6.0 [4.0 – 8.0]
20.5 [14.0 – 28.0]
11.0 [7.0 – 16.0]
2.0 [0.0 – 5.3]
270.0 [266.0 –
273.0]
62 (61.4)
16 (15.8)

loSSB
(n = 53)

59 ± 12
29 (29)
29.7 ± 6.7
62 ± 57
19 (19)
28 (28)
14 (14)
1.5 ± 0.2
12 (12)
24 (24)
4.7 ± 0.6
5.2 ± 1.5
3.8 ± 0.4
6.2 ± 4.8
10.9 ± 36.7
276 ± 146
155 ± 127
147 ± 41
106 ± 52
80 ± 34
46 ± 16
17.9 ± 12.7
21.7 ± 5.4
6.7 ± 3.1
20.4 ± 9.2
13.7 ± 7.8
4.9 ± 6.1
268.0 ± 4.6

60 ± 14
30 (30)
26.9 ± 6.0
66 ± 68
16 (16)
29 (29)
15 (15)
1.6 ± 0.3
5 (5)
32 (32)
4.6 ± 0.6
5.0 ± 1.0
3.8 ± 0.3
6.0 ± 3.2
13.2 ± 54.4
259 ± 163
134 ± 97
154 ± 47
87 ± 51
80 ± 45
56 ± 21
27.2 ± 17.8
23.8 ± 6.1
5.5 ± 3.4
23.2 ± 10.1
11.8 ± 8.4
3.1 ± 4.8
270.3 ± 4.1

p value
between
groups
0.662
0.605
0.029
0.770
0.284
0.624
0.870
0.084
0.032
0.349
0.632
0.285
0.948
0.745
0.799
0.594
0.373
0.471
0.069
0.987
0.007
0.003
0.081
0.076
0.154
0.251
0.103
0.009

22 (21.8)
10 (9.9)

40 (39.6)
6 (5.9)

0.050
0.050

Adapted from Tallman, et al. Nutrients, 2020 12(3), 797.
Values are expressed as median [interquartile range (IQR)], means ± SDs, or percentages. Statistics: 2-sample t
test, or Pearson chi-square test. BMI: Body Mass Index; DM, diabetes mellitus; Kt/V is a number used to quantify
hemodialysis (K, dialyzer clearance of urea; t, dialysis time; V, volume of distribution of urea, approximately equal
to patient’s total body water); *Renal vitamins included Nephrocaps, Renal Caps, and Nephrovite brands; CRP: Creactive protein; IL-6: Interleukin 6; IL-18: Interleukin 18; MCP-1: Monocyte Chemoattractant Protein-1; HDL:
high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol; Å: angstrom; 1BP hiSSB (n=44),
loSSB (n=43) 2Kt/V hiSSB (n=43), loSSB (n=45); 3Albumin hiSSB (n=46), loSSB (n=50); 4CRP, 4IL-6, 4MCP-1
hiSSB (n=46), loSSB (n=52); 5IL-18 hiSSB (n=46), loSSB (n=49); 6 large, 6 intermediate, and 6 small LDL, 6 mean
LDL size and 6LDL pattern hiSSB (n=46), loSSB (n=52).
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Table 18: Mean Daily Nutrient Intake According to Diet Cluster
Nutrient
All
hiSSB
loSSB
p value
(n = 100)
(n = 47)
(n = 53)
between
groups
Energy, kcals
2027 ±
2123 ±
1941 ±
0.029
414
432
381
Protein, g
86 ± 26
83 ± 21
88 ± 29
0.311
% kcals from
17 ± 4
16 ± 4
18 ± 4
0.008
protein
Fat, g
90 ± 24
89 ± 25
91 ± 24
0.713
% kcals from fat
40 ± 7
38 ± 6
42 ± 7
0.001
CHO, g
218 ± 65
249 ± 68
191 ± 50
< 0.001
% kcals from CHO
43 ± 8
47 ± 7
40 ± 7
< 0.001
Fiber, g
12 ± 4
13.2 ± 3.9 11.8 ± 4.5
0.095
Sugars, g
87 ± 45
115 ± 47
63 ± 23
< 0.001
Phosphorus, mg
833 ± 303 797 ± 260 864 ± 335
0.263
Iron, g
11.5 ± 4.5 11.3 ± 4.1 11.6 ± 4.9
0.800
Magnesium, mg
149 ± 64
150 ± 65
147 ± 64
0.852
Sodium, mg
2996 ±
3036 ±
2960 ±
0.695
961
1013
921
Potassium, mg
1500 ±
1487 ±
1512 ±
0.834
585
636
542
Zinc, mg
8.5 ± 4.1
7.4 ± 2.9
9.4 ± 4.8
0.017
Vitamin C, mg
58 ± 46
69 ± 55
48 ± 33
0.023
Vitamin E, mg
4.3 ± 3.1
4.4 ± 3.4
4.1 ± 2.9
0.628
Chromium (µg)
4.4 ± 6.9
2.9 ± 4.5
5.7 ± 8.2
0.031
Selenium (µg)
88.2 ±
79.6 ±
95.8 ±
0.023
37.8
35.3
38.7
Folic acid, mg
225 ± 108 230 ± 112 221 ± 105
0.707
Cholesterol, mg
412 ± 177 368 ± 153 452 ± 188
0.016
My plate
recommendations (%)
Grain
Vegetable
Fruit
Dairy
Protein

76 ± 33
33 ± 27
24 ± 33
13 ± 14
148 ± 64

75 ± 37
30 ± 25
32 ± 41
15 ± 14
132 ± 59

77 ± 30
35 ± 28
16 ± 21
12 ± 15
162 ± 65

0.749
0.369
0.023
0.306
0.019

Nutrient
Recommendations
Per renal Rx
Per renal Rx
10-35*
20-35*
45-65*
30*
< 50**
Per renal Rx
Per renal Rx
420*
< 2300**
Per renal Rx
11*
90*
15*
30*
55*
400*
Per renal Rx or
(< 200) [89]
Based on age and
gender [271]

Adapted from Tallman, et al. Nutrients, 2020 12(3), 797.
Values are means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test. *DRI, Dietary
Reference Intakes for males ages 51-70 [154]; CHO, carbohydrate; Rx, prescription; **2015-2020 Dietary
Guidelines for Americans recommends < 10 percent of calories per day from added sugars or 50 grams for a 2000
kcals [268].
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Table 19: Comparison of KDQOL Score by Selected Variables
Variable
Symptoms
Effects
Burden
Diet Cluster
hiSSB
73.8±13.1
74.1±17.7
48.8±26.7
loSSB
79.2±10.7
81.1±15.6
64.8±29.0
Gender
Male
77.4±11.6
78.2±16.8
56.3±28.6
Female
76.5±12.6
78.1±17.1
59.8±29.7
Tobacco use
Yes
74.8±14.1
77.9±21.5
56.3±33.2
No
77.9±10.9
78.3±14.4
58.5±27.1
Antidepressant use
Yes
66.1±17.6
66.3±24.9
42.5±29.1
No
78.2±10.7
79.6±15.3
59.6±28.6
Age
[β(se)]
0.36(0.15)*
0.52(0.19)*
0.32(0.36)
Vintage [β(se)]
-0.03(0.03)
0.06(0.03)
0.13(0.06)*
BMI
[β(se)]
-0.03(0.35)
-0.20(0.45)
0.56(0.80)

PCS

MCS

33.5±11.1
36.5±11.0

46.1±12.7a
53.0± 9.2a

35.4±11.7
35.0±10.3

50.7±12.5
50.6±10.0

35.0±10.7
35.3±11.3

50.6±12.6
50.7±11.0

28.0±9.2
36.1±11.0
0.03(0.13)
-0.06(0.02)*
-0.35(0.28)

43.6±10.9
51.5±11.3
0.27(0.14)
0.01(0.02)
-0.46(0.30)

Adapted from Tallman, et al. Nutrients, 2020 12(3), 797.
a
significant difference at 0.05. *significant association at 0.05. Values are mean ± SD. BMI: Body Mass Index.
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Figure 12: KDQOL Scores According to Diet Cluster
Adapted from Tallman, et al. Nutrients, 2020 12(3), 797.
SF 12 MCS: short form mental component summary; SF 12: short form physical component summary. Data is
presented as means ± SEM. In comparison with patients consuming a loSSB pattern, those consuming a hiSSB pattern
reported lower baseline KDQOL scores across all five domains and significantly lower baseline KDQOL scores for
the S12 mental composite subscale. hiSSB, n=20; loSSB, n=28. Data were compared using a Mann-Whitney U test
with a *p < 0.05 considered significant.

88
CHAPTER 5: RESULTS – SPECIFIC AIM THREE: TO ASSESS THE EFFECT OF
NUTRITION AND HEALTH STATUS IN A COHORT OF AFRICAN AMERICAN
MAINTENANCE HEMODIALYSIS PATIENTS ON MORTALITY
As of June 2020, data on mortality has been collected for two of the five clinics: Great
Lakes Dialysis and DaVita Kresge, for a total of 80 patients. Table 20 shows the differences in
mortality between deceased and survived participants. Subjects who consumed the hiSSB diet
were 1.62 95% CI (0.830 – 3.155) times more likely to die than those consuming the loSSB diet
(not significant). Deceased subjects had significantly lower HDL-C and intermediate HDL
cholesterol. Causes of death included cardiac arrest or congestive heart failure (22), stroke (2),
sepsis (2) and COVID-19 (3).
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Table 20: Mortality Data

Age (years)
Vintage (mo)
BMI (kg/m2)
Serum Potassium (mEq/L)
Serum Phosphorus (mg/dL)
Serum Albumin (g/dL)
Serum Creatinine (mg/dL)
CRP (mg/L)
IL-6 (pg/mL)
IL-18 (pg/mL)
MCP-1 (pg/mL)
Total Cholesterol (mg/dL)
Triglycerides (mg/dL)
LDL-C (mg/dL)
HDL-C (mg/dL)
Large HDL (mg/dL)
Intermediate HDL (mg/dL)
Small HDL (mg/dL)
Large LDL (mg/dL)
Intermediate LDL (mg/dL)
Small LDL (mg/dL)
Mean LDL Size (Å)
HiSSB, n (%)
LoSSB, n (%)

Deceased
(n = 25)
60 ±12
52 ±44
28.8 ±6.4
4.4 ±0.6
5.1 ±1.3
3.7 ± 0.3
8.1 ±2.7
7.3 ±6.0
4.0 ±5.7
258 ±115
138 ±57
152 ± 47
107 ±63
85 ±38
45 ±13
18.28 ±12.09
20.32 ±4.64
6.32 ±3.11
21.38 ±9.94
14.25 ±7.87
4.88 ±5.93
268 ±5.0
15 (39)
10 (24)

Survived
(n= 54)
58 ±13
61 ±57
28.5 ±6.8
4.6 ±0.6
5.1 ±1.1
3.8 ±0.3
9.5 ±2.6
6.0 ±3.1
20.1 ±63.2
269 ±184
156 ±144
152 ±45
91 ±45
81 ±43
53 ±19
23.93 ±16.42
23.52 ±5.79
5.98 ±3.48
22.58 ±10.16
13.04 ±8.63
4.00 ±5.61
270 ±4.0
26 (61)
31 (76)

p value
between groups
0.450
0.427
0.813
0.135
0.958
0.278
0.049
0.308
0.075
0.744
0.445
0.976
0.242
0.642
0.031
0.091
0.011
0.666
0.626
0.547
0.545
0.091
0.150

Values are expressed as means ± SDs, or percentages. Statistics: 2-sample t test, or Pearson chi-square test.
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CHAPTER 6: DISCUSSION
Characteristics of the Overall Study Population
The mean Kt/V for the entire cohort exceeded the minimum CMS quality standard of 1.2
[272]. Mean blood pressures reported for this cohort could not be compared to a standard as
specific targets are not currently recommended per the 2006 KDOQI Clinical Practice Guidelines
[273].
Mean serum ferritin for all patients was 757 ± 355 ng/mL; the 2001 KDOQI guidelines
recommended keeping serum ferritin at < 800 ng/mL [274]; however, in 2006, the guidelines were
updated to a target of < 500 ng/mL [275]. Analyses from the United States Dialysis Outcomes and
Practice Patterns Study reported a mean serum ferritin increase from 601 ng/mL in 2009 to 887
ng/mL in 2012 across facilities operated by two large dialysis organizations in the U.S. [276].
Higher serum ferritin levels observed among HD patients in the U.S., including this cohort, are
most likely resultant from the 2011 CMS bundled payment system, which included erythropoiesisstimulating agents (ESAs) and intravenous (IV) iron [277].
In this cohort, the mean hemoglobin levels met the 2007 KDOQI target guidelines of 11.0
to 12.0 g/dL for HD patients receiving ESA therapy [275]. Mean serum potassium levels were
found to be in an optimal range between 4.6 and 5.3 mEq/L [278]. Mean serum phosphorus was
also within the normal recommended range of 3.5 and 5.5 mg/dL [146]. However, mean serum
albumin was 3.8 ± 0.3 g/dL, which fell slightly below the KDOQI practice guideline
recommendations of 4.0 g/dL [258].
Anthropometrics
In this study, female HD patients were found to have a significantly higher BMI than males;
however, TSF and MAMC did not differ between genders, and serum creatinine levels were
actually higher for males. Anthropometry is often used to assess nutritional status; however, it is
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not always a good indicator of muscle mass for obese patients. Serum creatinine, which has been
shown to correlate closely with muscle mass in dialysis patients, may be a superior measure [279].
Furthermore, a significant association was found between HGS and serum creatinine, suggesting
that these two measures may reflect lean body mass better than MAMC for this group. Serum
creatinine and HGS may be a more reliable measurement to detect changes in muscle mass for
patients with BMI > 30 kg/m2.
Only 5% of the patients in this cohort met three out of the four criteria for PEW. Given
those patients too ill to enroll in PATCH would have met exclusion criteria, PEW prevalence may
have been underestimated in this AA MHD population. However, 27% of males and 19% of
females met the criteria for probable sarcopenia, which may be reflective of the advanced age of
this group.
Dyslipidemia and Inflammation
In comparison to males, female patients presented with significantly higher TC, HDL-C,
and large and intermediate HDL and large LDL subfractions. Given macronutrient distributions
were similar between both genders, differences in lipoprotein compositions were not likely
influenced from dietary composition. This finding of higher HDL-C among females is consistent
with literature for both HD and non CKD AA populations [280, 281].
Higher TG/HDL-C levels are risk factors for CV disease in the general population [282],
whereas higher levels of this ratio have been paradoxically associated with CV and overall survival
in ESRD HD patients. This contradiction may be explained by (1) non-traditional risk factors, such
as oxidative stress and inflammation, potentially transforming HDL from an anti-inflammatory to
proinflammatory particle, or (2) reflect higher levels of TG as an indicator of better nutritional
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status [283]. Patients in this PATCH subset with TG/HDL-C levels greater than 3.8 tended (nonsignificantly) towards lower levels of inflammatory markers.
Lipoprotein analyses revealed that both large and intermediate HDL subfractions were
more prevalent in contrast to small HDL subfractions. A shift from smaller to larger HDL
subpopulations has been previously reported in ESRD patients on HD [83, 284].
IL-18 activates PI3K/Akt and MEK/ERK1/2 signaling pathways, contributing to the
production of the chemokine MCP-1, which recruits inflammatory cells such as macrophages to
produce IL-6 as illustrated in Figure 11 [48]. IL-18 was found to be moderately positively
correlated with downstream molecules MCP-1 and IL-6, but not with CRP. As an acute phase
protein produced in the liver, CRP is secreted in response to IL-6 signaling, and to a lesser extent,
IL-1β and other pro-inflammatory cytokines [285]. 28% of IL-6 levels were below the detection
limit of the assay, therefore null findings for an association between IL-6 and CRP may be due to
assay sensitivity.
In the general population, women, persons with DM, and AA have higher levels of CRP
[286]. However, AA HD patients with higher levels of CRP have been found to have a paradoxical
survival advantage when compared to whites, but this advantage may be related to inflammation
stemming from causes other than CVD. Additionally, AA may be more resilient to the effects of
inflammation, potentially due to better nutritional status [117]. Preliminary mortality data show
that higher HDL-C and intermediate HDL subfractions, and serum creatinine (a surrogate for
LBM) were associated with a mortality benefit.
Egg Consumption and Health Outcomes
Negative outcomes on serum lipids, phosphorus, or PTH were not apparent between those
who reported consuming eggs and non-consumers. However, there are several limitations in
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interpreting this finding. First, given the observational nature of the study, causality cannot be
determined. Second, foods eaten with eggs, and not eggs per se, may be responsible for any
association. Third, non-consecutive 24-hr recalls, and not a food frequency questionnaire, was
used to collect data; therefore, actual egg consumption may not have been accurately captured.
Associations or correlations with outcomes and individual nutrients or foods may be the result of
confounding or lurking variables.
DII and Health Outcomes
DII showed a mean score of 3.1 ± 1.1 with a range of -0.54 to 5.83, indicating this sample
of AA MHD patients consume a proinflammatory diet. As a reference, the DII has been reported
as +4.0 for a fast food diet and -4.0 for the Mediterranean diet [200]. Similar to the findings in this
analysis, Kizil, et al. reported a mean DII score of 1.76 ± 1.26 (min, -0.37; max, 4.90) in a cross
sectional study of 105 Turkish HD patients [287]. Studies by different investigators have shown
inconsistent findings on associations between DII and inflammatory markers. High DII scores have
been positively associated with increased levels of high-sensitivity CRP (hs-CRP) in a cohort of
2567 postmenopausal women in the Women’s Health Initiative Observational Study [288]. Kizil,
et al. also found significant increasing trends across the tertiles of DII for CRP [287]. However, in
a Belgian cross-sectional study of 2524 generally healthy subjects, no significant associations were
observed between the DII and hs-CRP [289]. Since 2015, the DII has been used in over 200 studies
and has formed the basis for 12 meta-analyses. The research team responsible for developing the
DII recently made improvements to the DII construct by developing the E-DII to solve the
counteracting effect of negative correlations between energy density and nutrient density.
Given patients showed a preference for energy-dense, nutrient-poor foods, and because
energy is a component of the DII, these negative correlations were likely a complication in this
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analysis [290]. Furthermore, the inflammatory contribution from the diet may be overshadowed
by the production of inflammatory molecules in the uremic milieu.
Dietary Pattern Analysis
This study was not only the first published research to report on dietary patterns for HD
patients in the U.S., but also the first to examine dietary patterns with QOL in HD patients.
We found that only 3% of the entire study population consumed the minimum four to five
daily servings of fruits and vegetables recommended by the USDA for women and men aged 3150 [268]. Likely attributed to the low consumption of micronutrient rich foods, dietary intakes for
Mg, Zn, Cr, fiber, folic acid, and vitamins E and C fell below RDA guidelines for both groups.
Low intakes of micronutrients have similarly been found in other studies. In a cross
sectional study of 163 MHD patients (25% AA), plasma carotenoid levels were found to be
markedly reduced, a potential contributing factor to CVD risk [291]. In a dietary pattern analysis
of JHS participants, those consuming fast food diets had significantly lower serum concentrations
of the carotenoids lutein plus zeaxanthin and alpha tocopherol [292]. Although this latter study did
not include CKD participants, it examined typical dietary patterns and potential nutrient shortfalls
observed in an AA population.
The percentage of calories from carbohydrates fell below the AMDR range for the loSSB
group and was at the lower end of the range for the hiSSB group. Refined carbohydrates exceeded
DGA guideline upper limits for both groups, who also failed to meet the USDA recommendations
for grains.
Micronutrient intakes for Se, Zn, and Cr were significantly lower in the hiSSB cluster.
Lower QOL indicators have been associated with low intakes of Zn and Se. Due to lower physical
ability and fatigue in non-CKD patients, low Zn status has been associated with impaired QOL
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[293, 294]. Zn deficiency can contribute to disturbances in taste (dysgeusia) and smell, which may
lead to poor nutritional intake [295-297]. Low intakes of micronutrients such as Zn and Se may
have contributed to the lower QOL scores observed in the hiSSB group.
Inadequate micronutrient intake may have played a role in the atherogenic pattern B
phenotype, lower total HDL cholesterol and large HDL subfractions and tendency towards higher
levels of inflammation observed the hiSSB group. The lower levels of large HDL subfractions
observed in the hiSSB group may reflect failure of maturation of HDL2 from HDL3, potentially
due to oxidative modification of HDL or impaired LCAT activity.
Low Zn status has been associated with inflammation and lipid peroxidation [298]. Lower
Cr levels have been associated with malnutrition in HD patients [299], and with inflammation,
increased cardiovascular risk, and lower levels of HDL in non-CKD populations [300, 301].
Higher rates of hospitalization and death among HD patients have been associated with lower
concentrations of Se [302].
Although the burden of following a restrictive diet has the potential to impair QOL [303],
HD patients who control their diet experience enhanced general health and wellbeing and reduced
symptom burden [304]. Following a healthy diet has also been associated with improved QOL in
non-dialysis groups [305, 306]. Both lower mental and physical health scores were associated with
increased risk of cardiovascular events among blacks with hypertensive CKD in the African
American Study of Kidney Disease and Hypertension. The lower QOL scores may have resulted
from several factors including poor self-care, resulting in poor dietary compliance [307, 308]. Each
10-unit drop in the mental health score has been associated with a 12% higher death risk among
AA HD patients.
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In order to reduce phosphorus and potassium intake, HD patients are often instructed to
avoid dairy products, fruits, vegetables, and whole grains. At the same time, they are encouraged
to consume protein rich foods, such as HBV proteins. Sugar sweetened juices, “clear” sugar
sweetened carbonated beverages, and higher fat non-dairy products are often suggested to supply
phosphorus and potassium free calories. Efforts to restrict potassium, sodium, and phosphorus, are
perhaps also inadvertently encouraging the intake of sugar sweetened beverages, which can have
negative consequences.
There are several limitations in this study. First, it is unclear whether dietary patterns may
have influenced QOL or if self-perceived QOL affected dietary choices; therefore, causality cannot
be determined. Second, diet data was not collected for dialysis days, and may not represent usual
intake. Finally, micronutrient values may have been underestimated, since not all commercial
products in ESHA Food Processor SQL software package have complete information.
Mortality
Similar profiles for HDL subfractions were observed for both deceased patients and those
consuming a hiSSB diet pattern. Trends in the HDL subfractions for the deceased patients as
compared to the survived patients may be reflective of failure for maturation of HDL3 to HDL2 for
the deceased patients. Given the preliminary data, small sample size, and observational nature of
this analysis, it is too early to draw conclusions.
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CHAPTER 7: CONCLUSIONS AND RECOMMENDATIONS
The nutritional assessment data analyzed in this study consisted of objective data, such as
clinical chemistry, anthropometric measurements, and measures of dialysis adequacy and
subjective data, including diet recalls and QOL. Three different approaches to analyzing diet data
to document the extent to which diet is associated with health outcomes in AA MHD patients were
examined. Each approach provided valuable insight into nutrient shortfalls for AA patients
receiving HD and may be used to guide nutritional interventions.
In the first approach, a focus on macro and micronutrient intakes revealed that patients in
this cohort consume a macronutrient distribution range of 43/17/40 for carbohydrate/protein/fat. It
was found that intakes for sodium, phosphorus, and potassium exceeded recommended guidelines
by 76%, 22%, and 82%, respectively, and almost all patients fell below recommended intakes for
several micronutrients, including vitamins C, E, K, zinc, and magnesium. It was also found that
eggs, a food which is often limited due to phosphorus and cholesterol concerns, only accounted
for approximately 2-3% of the total energy intake for this AA HD population. No differences were
found for BMI, serum lipids, phosphorus, albumin, and PTH between those participants who
reported any egg consumption against those who did not report egg consumption.
Using an à priori approach to calculate the Dietary Inflammatory Index showed that this
group of patients consumed a proinflammatory diet, driven by low intakes of PUFA. After
dichotomizing the DII, no associations were found between plasma inflammatory biomarkers and
the higher DII group; however, with a homogenous population, the ability to robustly detect
differences between groups may have been impacted.
The third approach used an à posteriori method to derive dietary patterns driven by the
dietary data using a multivariate statistical technique. One important advantage of the à posteriori
approach is that it takes into account all aspects of the diet rather than focusing on predefined food
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groups or dietary indices, such as the DII. Two clusters were identified, revealing that lower
KDQOL scores were associated with a dietary pattern characterized by high intakes of sugar
sweetened beverages and reduced intakes of protein foods and vegetables. Those patients in the
high sugar sweetened beverage cluster were found to have significantly lower intakes of several
micronutrients, including Zn, Cr, and Se, which may have potentially contributed to the lower
KDQOL scores as well as lower levels of HDL cholesterol and large HDL subfractions observed.
All dietary analyses demonstrated that the majority of patients consumed an energy dense
diet, deficient in several micronutrients as most calories were derived from sugar sweetened
beverages and processed foods. Dietary patterns high in sugar sweetened beverages were found to
associate with negative health outcomes, including lower HDL-C, large HDL, mean LDL particle
size, higher BMI, and lower QOL scores. On the other hand, eggs, which may be limited in renal
diets due to phosphorus and cholesterol concerns, were not found to associate with negative health
outcomes.
Preventing nutrient shortfalls while ensuring adequate calories and protein while avoiding
excess intakes of phosphorus, potassium, and sodium remains a challenge. Providing nutritional
supplements may help bridge the gap for some nutrients, although HD patients are typically
prescribed renal specific vitamins, they provide only water-soluble B vitamins and vitamin C lost
through dialysis. Only a few renal specific vitamins provide additional micronutrients such as Zn,
Se, and vitamin E. Using a whole diet approach instead of focusing on individual nutrients may
not only improve the QOL for many renal patients who find following a restrictive diet a burden,
and thus abandons the diet altogether, but may also have a positive impact on other aspects of
health, such as lipoprotein profile, muscle mass, and inflammation.
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Further studies examining the impact of liberalizing the renal diet to include more whole
foods and fewer processed foods on health outcomes in a controlled setting with close monitoring
of nutrition and health indices are needed.
Additionally, the mortality benefit observed in the AA HD population is still unknown.
Further studies examining longevity benefit related to muscle mass, fat mass, genetics,
psychosocial status, inflammation, differences in mineral metabolism, vitamin D analogs dosage,
lipoprotein profiles, dietary patterns, and CVD should be conducted.
Examination into obstacles encountered by AA HD patients in following renal diet
restrictions, such as lack of access to healthy foods, reliance on ultra-processed foods, selfefficacy, and personal motivation may inform future interventions.
In light of advancements in HD procedures and new pharmacological interventions, the
benefit of adhering to renal dietary restrictions versus risk of PEW, inadequate micronutrient
consumption, lower QOL, and subsequent reliance on sugar sweetened and processed foods should
be examined.
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APPENDIX A: CASE REPORT FORM
Effects of Supplementing Palm Tocotrienols in Chronic Hemodialysis (PATCH)
IRB#123314MP4F
Screening and Baseline CRF Checklist
Date Completed

󠆴

Personal Details & Medical History

󠆴

Medication Profile & Hemodialysis Regimen

󠆴

Anthropometry, Body Comp & Muscle Strength

󠆴

Biochemical Data

󠆴

24 Hour Recall

󠆴

Appetite and Diet Assessment Tool (ADAT)

󠆴

Restless Legs Syndrome Rating Scale

󠆴

KDQOL

Subject Number:

Center Information:
󠆴DaVita Kresge Dialysis

󠆴Henry Ford Fairlane

󠆴Great Lakes Dialysis, LLC

󠆴DaVita Redford Dialysis

󠆴DaVita Highland Park Dialysis

󠆴Henry Ford West Pavilion

Initials
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INCLUSION CRITERIA
Yes

No

1. Patient is willing and able to give informed consent for
participation in the trial.

󠆴

󠆴

2. Male or Female, aged 18 years and above. Undergoing chronic
hemodialysis treatment for more than 3 months (life expectancy > 1 year).

󠆴

󠆴

3. Able and willing to comply with all trial requirements.

󠆴

󠆴

4. Willing to allow his or her /Physician/Nephrologist/General
Practitioner and consultant, if appropriate, to be notified of
participation in the trial.

󠆴

󠆴

If the answer to any of the questions above is no, the participant is not eligible
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EXCLUSION CRITERIA
Yes

No

1. Participants who have participated in another research trial
involving an investigational product in the past 12 weeks

󠆴

󠆴

2. History of functional kidney transplant 6 months before study entry;
anticipated live donor kidney transplant over the study duration;

󠆴

󠆴

3. Participants who are taking vitamin E- containing supplements >60 IU/d
during the past 30 days

󠆴

󠆴

4. History of poor adherence to hemodialysis or medical regimen

󠆴

󠆴

5. Participants who are currently on active treatment for cancer, excluding
basal cell carcinoma of the skin

󠆴

󠆴

6. Participants who have been diagnosed as HIV/AIDS and/or on the
anti-HIV therapy. (HIV seropositivity is not an exclusion criterion)

󠆴

󠆴

7. Patients taking anti-inflammatory medication, except aspirin<325 mg/d,
over the past 30 days

󠆴

󠆴

8. Female participant who is pregnant, lactating or planning pregnancy
during the course of the trial

󠆴

󠆴

9. Participants who are receiving nutritional support (i.e. enteral and
intra-venous route)

󠆴

󠆴

10. Patients using a temporary catheter for dialysis access at baseline or
patients receiving a graft/fistula within the 6-month study period

󠆴

󠆴

11. More than two hospitalizations within the last 90 days or one hospitalization 󠆴
within the 30 days preceding enrollment

󠆴

󠆴

󠆴

12. Any other significant disease or disorder which, in the opinion of their
nephrologist, may either put the participants at risk because of
participation in the trial, or may influence the result of the trial,
or the participant's ability to participate in the trial.

If the answer to any of the questions above is yes, the participant is not eligible
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PERSONAL DETAILS
Dialysis Shift: 󠆴 Mon/Wed/Fri
Time of Dialysis Shift:
Gender:

󠆴Tues/Thurs/Sat

___am/pm

M/F

Duration: _____________ hrs.
Age:

years old

Date of Birth (dd/mm/yy):
Ethnicity: 󠆴

󠆴Caucasian

󠆴African American

󠆴Asian

󠆴Other:

󠆴Hispanic/Latino

MEDICAL HISTORY
What is the cause of kidney failure?
󠆴Unknown

󠆴Nephronophthisis

󠆴Diabetes Mellitus

󠆴APKD (Adult Polycystic Kidney Disease)

󠆴Hypertension

󠆴Gout Nephropathy

󠆴HIV-Nephropathy

󠆴Toxic Nephropathy

󠆴Kidney Stone

󠆴SLE (Systemic Lupus Erythematosus)

󠆴Glomerulonephritis

󠆴Others:

Start Date of HD: (mm/yy)

/

Kidney Transplantation?

󠆴Yes

󠆴No

Parathyroid Gland Removed?

󠆴Yes

󠆴No

Diabetes?

󠆴Yes

󠆴No

Tobacco Use?

󠆴Yes

󠆴No

Secondary HPTH?

󠆴Yes

󠆴No

Hepatitis C ?

󠆴Yes

󠆴No

Current Diagnoses:

104
MEDICATION PROFILE
Prescribed Medications
Renal vitamin/supplement
Lactulose
Calcium (carbonate/acetate)
Sevelamer
Lanthanum
Other P binder
Calcimimetic
Iron
Vitamin D
ESA
Insulin
OHA
Statin
Ca channel blocker
Alpha/beta blocker
ACE inhibitor/ARB
Others:

Name

Dosage/Frequency

HEMODIALYSIS PRESCRIPTION
Is the dialyzer reused? Yes, How often?

󠆴No

Times

Type of dialyzer membrane:

Polysulfone

Cellulose triacetate

Types of vascular graft being used:

󠆴Arterio venous fistula

Other:

󠆴Arteriovenous graft (AVG)
󠆴Venous Catheter
Type of dialysate buffer:

󠆴Acetate
󠆴Low calcium

󠆴Normal Calcium

󠆴High Calcium

󠆴Bicarbonate
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ANTHROPOMETRIC DATA
Measurements

Date

Target Weight (kg)
Height (cm)
Post dialysis weight (dry weight)
Body Mass index (kg/m2)
Average IDWG
Average UFR
Average BP

MUSCLE STRENGTH
Hand Grip Dynamometer
Hand Grip Strength (kg)
Left (L) or
Dominant
Right (R)
Hand
hand

Avg

SD

CV

Test #1

Test #2

Test #3

BODY COMPOSITION -- MUSCLE MASS MEASUREMENTS
1st measure
Mid-arm circumference
(cm)
Triceps skinfolds (mm)

2nd measure

Mean
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BIOCHEMICAL DATA
Renal Profile (Pre-Dialysis)
Pre BUN (mg/dL)
Post BUN (mg/dL)
Creatinine (mg/dL)
Sodium (mEq/L)
Potassium (mEq/L)
Corrected Calcium (mg/dL)
Phosphorus (mg/dL)
Serum Albumin (g/dL)
Total Cholesterol (mg/dL
Triglycerides (mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
Glucose (mg/dL)
HgbA1C (g/dL)
Hemoglobin (g/dL)
Hematocrit (%)
Serum Fe (μg/dL)
Serum 󠆴TIBC 󠆴(μg/dL)
TSAT (%)
Ferritin (ng/mL)
Kt/V
URR
nPCR (g/kg/day)
hsCRP (mg/L)
PTH
WBC
Vit D

Date

Test Result

Normal Range
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24-hour dietary recall

Meal

Dialysis Day or Non-Dialysis day
Home
(H)/Outs
ide of
Home
(O)

Food Eaten

Quantity
(c, tsp. oz.,
g)

Preparation
Method (fried,
grilled, roasted,
stewed)

Source of
food (fresh,
frozen,
canned, etc.)
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APPETITE AND DIET ASSESSMENT TOOL (ADAT)
During the past week (7 days), how would you rate your appetite?
1 = Very Good
2 = Good
3 = Fair
4 = Poor
5 = Very Poor
2. Have you had a change of appetite in the past week (7 days?)
0 = no
1 = Yes
3. 󠆴If 󠆴you 󠆴answered 󠆴“yes” 󠆴to 󠆴#2, 󠆴how 󠆴has 󠆴your 󠆴appetite 󠆴changed?
1 = Increased
2 = Remained the same
3 = Decrease
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APPENDIX B: DIETARY ANALYSIS OUTPUT EXAMPLE

Note: Partial screenshot of ESHA Food Processor SQL software’s dietary analysis spreadsheet
report from one subject/one day’s meal entry
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APPENDIX C: KIDNEY DISEASE QUALITY OF LIFE (KDQOL) SURVEY
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In the United States, African Americans (AA) suffer a disproportionate burden of ESRD,
accounting for 35% of all dialysis patients, and are 3.7 times more likely to progress to ESRD than
whites. This increase in CKD risk is partially attributed to higher rates of hypertension, diabetes
mellitus, and cardiovascular disease. Paradoxically, once on hemodialysis, AA have a survival
advantage over whites, likely due to multiple factors including nutritional status, inflammation,
psychosocial status, and genetic variation.
Although both the dialysis procedure and pharmacological treatments are effective at
reducing the uremic toxin load, HD patients are still encouraged to adhere to strict dietary
guidelines. In an effort to avoid foods high in phosphorus and potassium, patients requiring HD
have limited intakes of fruits, vegetables, nuts, legumes, dairy, and whole grains. Associated with
reduced consumption of foods naturally rich in phytochemicals, such as carotenoids and
polyphenols, is a potential for the loss of benefit from the antioxidant and anti-inflammatory
activities associated with their intake.
ESRD patients on HD suffer from excessive oxidative stress, which has been associated
with an increased risk for cardiovascular disease. Mortality due to CVD is 20 times higher than in
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the general population due to both traditional and nontraditional risk factors such as protein energy
wasting, insulin resistance, anemia, oxidative stress, and inflammation. The HD procedure itself
results in a significant loss of antioxidants, while the bioincompatibility of dialyzers and dialysate
trigger the production of free radicals.
Nutritional approaches to improve outcomes for ESRD patients on HD have evolved over
time and reflect technological advances in renal replacement therapy. Focus in research has shifted
from restriction of individual nutrients and foods to examining diet patterns associated with
improved outcomes and mortality.
Two main analytical approaches used to identify dietary patterns in nutritional
epidemiology are à priori (hypothesis-driven) and à posteriori (data-driven) methods. À priori
methods are based on indices of diet quality or nutritional health defined scores and assess the
extent to which a subject complies with the predefined dietary pattern, whereas à posteriori
methods use multivariate statistical techniques to derive dietary patterns empirically based on the
actual diet in a specific population.
Health outcomes in AA maintenance hemodialysis patients and derived dietary patterns
using both an à posteriori and an à priori method were examined.
The Dietary Inflammatory Index (DII), à priori method, failed to show any correlation with
inflammatory or anthropometric indices. DII showed a mean score of 3.1 ± 1.1 with a range of 0.54 to 5.83, indicating patients consumed a proinflammatory diet. The null association between
diet and inflammatory markers (CRP, MCP-1, IL-6 and IL-18) may reflect that the inflammatory
contribution from the diet is overshadowed by the production of inflammatory molecules in the
uremic milieu.
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A cluster analysis, an à posteriori method, was performed using the k-means algorithm, a
nonhierarchical clustering method which classifies participants into non-overlapping groups based
on Euclidean distance, to obtain dietary patterns. Two major dietary patterns were identified:
(Cluster 1) a high “sugar sweetened beverage” pattern (hiSSB) and (Cluster 2) a low “sugar
sweetened beverage” pattern (loSSB). The hiSSB dietary pattern was characterized by higher
energy contributions from calorically sweetened soft and juice drinks (p < 0.001) and poultry (p <
0.05), whereas the greatest energy contributors to the loSSB group was unprocessed red meat (p <
0.05), fish and shellfish, (p < 0.05), and custard style desserts such as puddings, ice cream, and
cheesecake (p < 0.05). Compared to those in the loSSB dietary pattern cluster, patients in the hiSSB
cluster scored lower baseline values on all five KDQOL domains and significantly lower on the
S12 mental composite domain (p < 0.026).
All dietary analyses demonstrated that the majority of patients consumed an energy dense
diet, deficient in several micronutrients as most calories were derived from sugar sweetened
beverages and processed foods. Future studies aimed at interventions to examine the effects of
liberalizing the standard renal diet to deemphasize phosphorus and potassium rich foods and allow
whole and minimally processed foods are needed.
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